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Pharmaceuticals and personal care products are a growing concern in the aquatic 
environment.  Compounds from the class of non-steroidal anti-inflammatory drugs are 
commonly detected in surface waters and have the potential to negatively affect aquatic 
organisms.  The purpose of this experiment was to determine the acute and chronic 
effects of ibuprofen on rainbow trout (Oncorhynchus mykiss).  Cyclooxygenase (COX) 
activity, vitellogenin (VTG) concentration and ethoxyresorufin-O-deethylase (EROD) 
activity were evaluated following waterborne ibuprofen exposure of trout to 1 and 10 
mg/L in the acute exposure and 1, 32 and 1000 µg/L in the chronic exposure, along with 
an experimental control, E2 control of 1000 µg/L and an E2-ibuprofen mixed treatment.  
Ibuprofen did not inhibit COX enzyme activity in either gill or kidney tissue.  To evaluate 
the estrogenic effects of ibuprofen, VTG concentrations were measured; by the end of the 
56 day chronic exposure VTG concentrations significantly increased in all of the 
ibuprofen treatments relative to the controls.  EROD activity may have been inhibited by 
ibuprofen but definitive conclusions could not be made.  These findings indicate that 
more research needs to be done studying ibuprofen in aquatic systems. 
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1.0 Literature Review 
1.1 Introduction 
Chemicals used for the prevention and treatment of illness, as well as for 
individual hygiene, can be collectively described as pharmaceuticals and personal care 
products, or PPCPs (Corcoran et al., 2010).  The frequency and modes of their use makes 
it likely that PPCPs will ultimately enter water systems and thus PPCPs have become a 
growing concern in aquatic environments (Bound & Voulvoulis, 2004).  Research has 
shown that there is a direct correlation between the types of pharmaceuticals commonly 
utilized in society and their presence within the environment (Corcoran et al., 2010).  
One such class of PPCPs are non-steroidal anti-inflammatory drugs (NSAIDs).  NSAIDs 
have the ability to pass through wastewater treatment plants (WWTPs) and are the most 
documented pharmaceutical in water systems (Santos et al., 2010).  While it is accepted 
that these chemicals are present in the environment, further research is needed to 
elucidate their effects on non-target aquatic organisms. 
 
1.2 Pharmaceuticals in the Environment 
 Pharmaceuticals and personal care products have been detected in the 
environment since the 1970s but it was not until recently that growing concerns about 
potential environmental effects made them the focus of research.  Researchers discussed 
the effects of estrogenic compounds found in activated sludge on organisms in the mid 
1960s but this was largely ignored (Marsalek, 2007).  Now, as more work goes into 
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studying these chemicals a new area of study is emerging known as ‘Pharmaceuticals in 
the Environment’, or PIE (Khetan & Collins, 2007).  
Discharge of PPCPs into the environment occurred unregulated for decades even 
though it was known that the active compounds may affect non-target organisms 
(Daughton & Ternes, 1999).  Paralleling the emergence of new, sophisticated analytical 
instrumentation and techniques to measure these drugs, more information is being 
gathered on the appearance, persistence and activity of PPCPs in the environment 
(Daughton & Ternes, 1999).  It has been estimated that there are approximately 2000 to 
3000 different compounds used as human pharmaceuticals (Marsalek, 2007).  This 
number is unquestionably going to grow as the pharmaceutical industry increases the 
effectiveness of the biologically active ingredients.  Work is continuously being done to 
increase the potency, bioavailability and degradation resistance of pharmaceuticals 
(Khetan & Collins, 2007).  While these characteristics make the pharmaceutical more 
desirable as a treatment method, it is these same characteristics that increase the potential 
toxicity in the environment. 
 Before the effects on the environment can be discussed in relation to PPCPs, it 
must first be understood how these chemicals make their way into natural systems.  For 
drugs to make their way into the environment, they first need to be used.  When 
analyzing worldwide sales of pharmaceuticals, North America dominates the market with 
45%, which is not closely followed by Europe (13%) and Japan (10%) (Corcoran et al., 
2010).  Global pharmaceutical sales for 2010 were estimated at almost 800 billion US 
dollars (IMS Health, 2010a).  Focusing on Canada, Intercontinental Medical Statistics 
(IMS) Health stated that when studying the top 10 dispensed therapeutic classes in 2010 
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over 504 million prescriptions were filled (IMS Health, 2010b).  While this number may 
seem large it is significantly increased when all of the drugs available without 
prescriptions, called over-the-counter drugs, or OTCs, are considered, making these 
values greatly underestimated (IMS Health, 2010b; Daughton & Ternes, 1999; Ternes, 
1998). 
 The sheer volume of PPCPs used in society is directly linked to their entrance into 
the environment.  Many of the chemicals detected in water systems are compounds from 
classes of pharmaceuticals linked to problems associated with Western society, such as 
pain, anxiety and depression management and cholesterol regulation (Corcoran et al., 
2010).  This is due to the fact that many pharmaceuticals are excreted as the parent 
compound or active metabolites through urine and feces.  Thirty to ninety percent of the 
administered dose is excreted as the active chemical, depending on the drug (Halling-
Sørensen et al., 1998).   
Treated wastewater is the main route for pharmaceuticals to enter the environment 
(Kotchen et al., 2009).  When a person takes a medication, prescribed or illicit, most of 
the drug passes through the body and is introduced into the sewage system (Bound & 
Voulvoulis, 2004).  The chemical may remain as the active parent compound or may be 
metabolized into a form which is more or less biologically active than its original state.   
In addition to excretion, PPCPs are introduced into the sewage system by 
improper disposal techniques.  A study by Kotchen et al. (2009) found that many people 
improperly disposed of their pharmaceuticals by flushing them down the toilet or sink.  
Through the use of a survey, the researchers not only discovered this fact but also that 
many people did not think of the consequences of this practice.  Another minor route of 
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PPCP entry is from washing and bathing.  Once in the system, the pharmaceuticals make 
their way to the treatment plants. 
 
1.3 Wastewater Treatment Plants 
1.3.1 Treatment Processes 
 As stated previously, WWTP effluents are the main route of PPCPs into the 
environment.  Upon excretion via urine and feces, these chemicals are able to enter 
municipal sewage treatment plants (Choi et al., 2006).  A schematic of the general 
treatment phases of a standard WWTP can be found in Spellman (2009) (Figure 1).  The 
general treatment stages can be defined as pretreatment, primary treatment, secondary 
treatment, tertiary treatment and sludge treatment (Spellman, 2009). 
 An initial pretreatment step is the first stage for incoming waters (Carballa et al., 
2004).  Large contaminant material, such as garbage and other waste products, are 
physically removed from the influent waters by the use of coarse bar screens (Carballa et 
al., 2004).  This process may be supplemented by other removal techniques, including 
shredding and grit removal (Spellman, 2009).  Once the physical removal of large 
materials is accomplished, the partially cleaned influent waters move into primary 
treatment. 
 In primary treatment, influent waters are pumped into large tanks called clarifiers, 
or sedimentation tanks (Carballa et al., 2004).  In these circular holding basins, the water 
is held to allow for separation of heavier particulate material.  Some material will settle to 
the bottom, such as dirt, and some will float to the top, such as lipids.  Once this has 
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occurred, mechanical arms sweep the tanks and remove the particulate matter as sludge 
(Spellman, 2009).  This sludge is collected for further processing. 
 Secondary treatment is the next stage in the purifying process (Carballa et al., 
2004).  From the clarifiers, the wastewater moves into the biological reactor.  The 
biological reactors are specialized tanks where degradation takes place using controlled 
bacterial populations (Spellman, 2009).  Under either aerobic or anaerobic conditions, the 
bacteria degrade or sequester contaminant material before the water moves to secondary 
sedimentation tanks (Caraballa et al., 2004; Fent et al., 2006).  This second sedimentation 
tank is to allow for any bacteria that that may have escaped the biological reactor to be 
recollected as sludge and added back into the treatment system.  Excess sludge from this 
stage is combined with sludge collected from the primary treatment and processed for 
other uses, such as dispersal on agricultural fields (Santos et al., 2010). 
 Depending on the type of WWTP and its location, the treatment water may be 
released back into the environment or may go through a final treatment stage, known as 
tertiary treatment.  This generally consists of final disinfection, such as ozonation or 
chlorination, as well as treatment steps to remove nutrients through metal flocculation 
(Daughton & Ternes, 1999).  The United States commonly uses chlorine as a disinfectant 
whereas European countries, and Canada, generally use ozonation (Synder et al., 2003).  













Figure 1: General schematic of WWTPs including treatment phases.  Treatments include 
pretreatment, primary treatment, secondary treatment and tertiary treatment for influent 
waters.  Sludge treatment processes the solid material collected from the water treatment 







1.3.2 Factors Influencing Removal 
PPCPs are removed through two main processes involved in sewage treatment: 
adsorption and biological degradation (Fent et al., 2006; Santos et al., 2010).  Removal of 
pharmaceuticals with suspended particulate material is highly dependent upon the 
chemical structure of the individual compounds.  Their hydrophobic and electrostatic 
interactions with particulate material are essential for removal.  Compounds with low 
adsorption coefficients will tend to stay in the aqueous phase (Carballa et al., 2004).  This 
is also the case with acidic pharmaceuticals, such as NSAIDs, with low pKa values.  At 
neutral pH, these compounds will be in their ionic form and will have a greater tendency 
to stay within the water column and not precipitate out (Fent et al., 2006).  When 
compounds are mainly found in the dissolved phase, biological degradation becomes the 
main removal method.  Removal is often imperfect due to the fact that WWTPs were not 
designed to handle pharmaceuticals (Christen et al., 2010; Khetan & Collins, 2007).   
Microorganisms in the activated sludge systems are most efficient at removing 
carbon, nitrogen and other microbial contaminants.  Many PPCPs are synthetic chemicals 
which are not natural to the environment (Carballa et al., 2004).  Because they are not 
naturally found they may not be effectively removed.  There are two main schools of 
thought about this reduction in removal efficacy.  First, it is believed that removal is low 
due to the tendency for the chemicals to be present in trace amounts (Christen et al., 
2010).  Also, with the pharmaceutical industry booming, new pharmaceuticals are 
continuously being introduced to the ever expanding market.  This means that more and 
more pharmaceuticals are passing through WWTPs that the bacteria in the reactors have 
never encountered previously (Daughton & Ternes, 1999).  Since the bacteria have never 
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‘seen’ the new chemicals before, there is no selective pressure for them to have the 
mechanisms necessary for their degradation. 
 In addition to the actual mechanisms within the WWTPs that facilitate PPCP 
removal, there are other external factors that influence the degree to which the drugs are 
removed.  The construction of the treatment facility itself, along with the types of 
treatment steps performed, affect removal.  One very significant factor is retention time, 
or the length of time it takes influent waters to pass through the treatment stages (Fent et 
al., 2006).  The longer the influent waters remain in each treatment step the greater the 
potential for degradation.  Longer retention times may help to counteract the low 
concentration of the PPCPs and help to increase biological degradation.  Another fact is 
seasonality, which can greatly alter removal efficiency in the biological reactors, by 
which variation in light intensity and temperature are key factors in the removal process 
(Khetan & Collins, 2007).  A study conducted in Finland measured the concentrations of 
a number of drugs, including ibuprofen, in effluent waters over 3 seasons.  It was found 
that in winter months there was a significant reduction in drug removal which resulted in, 
depending on the pharmaceutical, up to a 5 fold increase in their concentrations in the 
effluent waters (Khetan & Collins, 2007).  It is a combination of all of these factors that 
leads to pharmaceuticals and other personal care products entering environmental 
systems at biologically relevant concentrations. 
 
1.4 Environmentally Relevant PPCP Concentrations 
 Once through the WWTPs, pharmaceuticals can be detected in effluent waters, 
and in surface waters, in the ng/L to µg/L range (Corcoran et al., 2010).  The factors 
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influencing these concentrations have already been discussed (ie. use in society, human 
metabolism and excretion, variations in WWTP removal efficiencies) but it should be 
noted how extensively these chemicals can be found within the environment.  Pristine 
environmental areas, far from urban centers with large populations, have been sampled 
and pharmaceutical drugs detected (Daughton & Ternes, 1999).  Any place that humans 
visit has the potential to be contaminated with these drugs, unlike other pollutants such as 
pesticides.  Pristine national parks, for example, commonly have aging sewage systems.  
If there is enough human traffic which use these systems, PPCPs can leach into the 
surrounding environment and through rainfall and flooding be carried away (Daughton & 
Ternes, 1999).  Also, the reuse of sludge from WWTPs can increase environmental PPCP 
concentrations.  Some chemicals become adsorbed onto particulate material during the 
treatment process and therefore become associated with the sludge.  When this sludge 
material is used on agricultural fields as a fertilizer, the highly concentrated PPCP content 
can run off into nearby surface and ground water sources (Santos et al., 2010)  It appears 
that as these compounds become more common in everyday life no area will be 
completely free of their influence. 
 Research into PPCPs in the environment has increased significantly.  A summary 
by Santos et al. (2010) showed that the most detected pharmaceuticals in environmental 
systems are non-steroidal anti-inflammatory drugs (NSAIDs) (Figure 2).  This is 
expected because common types of NSAIDs, such as ibuprofen and naproxen, are readily 
available as OTCs, such as Advil® and Aleve® respectively.  The more these drugs are 
taken, the more readily they will be detected in water systems.  The remainder of this 
work will focus on NSAIDs and their effects in aquatic environments. 
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 Previously, most of the research done on PPCPs was focused in Europe (Metcalfe 
et al., 2003b).  In recent years, more researchers have been looking at Canadian water 
systems and analyzing which PPCPs are commonly detected.  The main studies done are 
by Metcalfe et al. (2003a,b) and Lishman et al. (2006).  These articles detected the 
presence of NSAIDs in Canadian regions. 
 While some chemicals can be readily broken down in surface waters through 
photodegradation, such as naproxen, and others persist for relatively short periods of 
time, they still pose an ecological threat (Isidori et al., 2005).  This is because PPCPs are 
classified as being ‘pseudo-persistent’, meaning that while they may not persist in the 
environment they still may cause effects from the continuous addition (Durán-Alvarez et 


















Figure 2: Relative percentages of PPCPs measured in the environment based on 


































1.5 Endocrine Disruptors 
1.5.1 What are Endocrine Disruptors? 
 One of the main communication systems in the body is the endocrine system 
(Vogel, 2004).  It is responsible for sending hormone signals and regulating body 
functions necessary for growth, reproduction and behaviour (EPA, 1997; Vogel, 2004).  
Therefore, any compound that disrupts or causes an imbalance in the natural homeostasis 
of the body can be described as an endocrine disruptor (Labelle, 2000).  Endocrine 
disrupting compounds (EDCs) are any chemical agent that interferes with the synthesis, 
secretion, transport, binding, function or elimination of hormones (EPA, 1997).  Any 
malfunctions of these body systems can lead to disease (Vogel, 2004). 
 There has been some debate over how these chemicals should be classified 
because they are usually grouped by action rather than by chemical structure.  The 
general consensus is that there are 3 classes of EDCs; estrogenic chemicals, androgenic 
chemicals and thyroidal chemicals, although anti-estrogenic and anti-androgenic 
chemicals are also common (Synder et al., 2003).  Regardless of class, all EDCs act in a 
few select ways.  They can act as mimics, blockers or triggers (Labelle, 2000).  Agents 
that mimic hormones trick the organism into perceiving that they are the natural 
compound, eliciting effects that would arise from normal hormonal interaction (Labelle, 
2000).  EDCs may also inhibit the activity of certain enzymes (Vogel, 2004).  Without 
the activity of specific enzymes, metabolic pathways may be disrupted.  Lastly, these 
chemicals may also act as triggers, abnormally initiating pathways by modifying 
hormone receptor levels or altering synthesis patterns (Labelle, 2000).  These effects are 
the reasons why the body possesses mechanisms to excrete these chemicals. 
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1.5.2 PPCPs as EDCs 
As discussed previously, PPCPs may enter the aquatic system as the parent 
compound or as metabolites, because most compounds are metabolized before removal 
from the body (Halling-Sørensen et al., 1998).  The mechanisms of metabolism for 
xenobiotic compounds are referred to as Phase I and Phase II reactions (Daughton & 
Ternes, 1999).  Collectively, these two phases successively increase the polarity of the 
compound, enhancing its excretion.  Monooxygenases, such as the cytochrome P450 
enzymes, are utilized in Phase I reactions (Daughton & Ternes, 1999).  These enzymes 
add reactive functional groups to the PPCP molecules while Phase II reactions use 
conjugation with glucuronic acid, also called glucuronidation, to increase the 
hydrophilicity of the molecules (Daughton & Ternes, 1999).  The more hydrophilic the 
compound is, the more readily it will be eliminated from the body. 
 The reason PPCPs are such a concern in the aquatic environment as endocrine 
disruptors is that these chemicals are designed to target specific metabolic and molecular 
pathways (Christen et al., 2010).  Humans take these drugs for specific biological reasons 
and these same effects can be caused in non-target organisms (Bound & Voulvoulis, 
2004).  Similar pharmacodynamic effects can be seen in aquatic wildlife at higher trophic 
levels, such as fish and amphibians, because many possess similar metabolic pathways, 
receptors and biomolecules (Brown et al., 2007; Santos et al., 2010).  For example, if a 
pharmaceutical is designed to inhibit an enzyme in humans, fish which possess that same 
enzyme may also be affected upon exposure to that chemical.   
Complexity arises from the fact that not all human pharmaceuticals on the market 
have well defined modes of action (Daughton & Ternes, 1999; Christen et al., 2010).  
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Some drugs, like ibuprofen, have been well studied and the exact metabolic target is 
known but this is not always the case with newer pharmaceuticals.  Also, aquatic 
organisms may experience effects from PPCPs that are not expected.  Human 
pharmaceuticals commonly have listed side-effects but these side-effects may be more 
severe in non-target species because of slight differences in physiology.   
The impact of PPCPs in the environment is also not solely based upon the 
concentration of the parent compound but also upon the presence of any metabolites or 
transformation products.  It was previously mentioned that the NSAID naproxen 
undergoes photodegradation in surface waters.  Toxicity studies utilizing small 
invertebrate species have shown that some of these photoproducts are in fact more toxic 
than that of the parent compound (DellaGreca et al., 2004; Isidori et al., 2005).   
  
1.5.3 Knowledge Gaps in EDC Research 
While there is a significant knowledge base discussing the potential effects of 
PPCPs in the environment as endocrine disruptors, there is little evidence showing effects 
to aquatic organisms on the population level (Corcoran et al., 2010).  This is because the 
field is dominated by acute studies.  Most research is based on short term laboratory 
studies performed at high concentrations (Corcoran et al., 2010).  This does not represent 
what occurs in nature and would only be relevant to discuss spills where large 
concentrations of PPCPs are accidentally introduced into the environment (Santos et al., 
2010).   
Chronic studies, as well as those that look at the bioconcentration of PPCPs in 
organisms, are lacking (Brown et al., 2007; Santos et al., 2010).  Chronic exposures are 
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defined as experiments in which organisms are exposed to chemicals over long periods of 
time or a substantial portion (generally > 10%) of their life cycle (Crane et al., 2006).  
With PPCPs being continuously discharged into the environment at low levels, aquatic 
organisms are potentially exposed over their entire life span.  Although emitted in low 
concentrations, drugs have the ability to bioaccumulate in the tissues of wildlife.   
Brown et al. (2007) proposed a model to calculate the degree to which different 
pharmaceuticals accumulate in fish species.  Concentration in the tissues of the fish 
depends not only on the physicochemical properties of the compounds but also their 
bioavailability.  In relation to those dissolved drugs which are taken up across the gills, 
drugs that are associated to particulate material through electrostatic interactions are less 
available to the fish and therefore will be present in lower concentrations within the 
organism (Brown et al., 2007).   
A final factor that needs to be analyzed in relation to the endocrine disrupting 
ability of PPCPs is the fact that in the environment these chemicals are not present in 
isolation.  In laboratory settings, pharmaceuticals are generally evaluated as individual 
chemicals but in wastewater effluents they are present as part of complex mixtures.  
Research into how these chemicals interact within mixtures needs to be undertaken 
(Santos et al., 2010).  Some chemicals have the ability to modify the toxicity of others, so 
the expected effects of one pharmaceutical may be different when that chemical is in the 
presence of another.  There have been only a few studies published looking specifically at 
mixture effects.  Studies by Cleuvers (2003, 2004) using small invertebrate organisms 
demonstrated that a mixture of PPCPs caused an increased effect on the test subjects in 
comparison to when the individual chemicals were exposed in isolation.  
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While the gaps in the field of environmental pharmaceutical research are large, 
small steps need to be taken in order to fill them.  This can be done by first studying those 
compounds which are detected with the highest frequency, which are the non-steroidal 
anti-inflammatory drugs. 
 
1.6 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
1.6.1 Brief History and Introduction 
 The use of chemical compounds to treat pain and inflammation is not a modern 
notion.  It can be dated back to ancient Egypt, where elders applied treatments of dried 
myrtle leaves to those with ailments (Vane & Botting, 1998).  In the body, inflammation 
is the response of living tissue to injury (Vane & Botting, 1995).  This initiates a cascade 
of events including enzyme activation, extravasation of fluids, cell migration and tissue 
breakdown and repair (Vane & Botting, 1995).  It was this notion of pain and 
inflammation management that caused researchers to study the physiological effects that 
take place, leading to J. R. Vane’s 1971 discovery of a class of pharmaceuticals that can 
inhibit these reactions, known as non-steroidal anti-inflammatory drugs (Cha et al., 
2006).  In summary, Vane demonstrated that NSAIDs inhibit the cyclooxygenase (COX) 
enzymes responsible for prostaglandin (PG) production necessary for the inflammatory 
response.  Although this breakthrough did not occur until the 1970s, inquiry into the 






1.6.2 Prostaglandins and Cyclooxygenase Enzymes 
 Before a discussion of how NSAIDs act to inhibit the inflammatory response in 
the body, the response itself needs to be discussed.  The starting point for this concept is 
understanding prostaglandins.  Prostaglandins play a variety of biological functions.  In 
addition to inflammation and pain, PGs are necessary for homeostasis in a variety of 
pathways such as maintaining the gastric mucosa, regulating kidney blood flow and 
various reproductive mechanisms (Fent et al., 2006).  PGs are part of a larger group of 
biomolecules called prostanoids.  This group then falls under the larger category of 
eicosanoids (Cha et al., 2006).  Eicosanoids are evolutionarily conserved bioactive lipid 
molecules consisting of 20 carbon fatty acid molecules (Cha et al., 2006).  Any altered 
expression of these compounds can lead to pathophysiological conditions (Ishikawa & 
Herschman, 2007).  
 PGs are present in most cells, although these compounds are rapidly synthesized 
in response to stimuli rather than being stored (Ruggeri & Thoroughgood, 1985).  They 
are produced through the activity of the cyclooxygenase enzymes.  COX enzymes, also 
called prostaglandin endoperoxide synthases (PGHS), are present in two isoforms that are 
responsible for PG production.  COX are bifunctional enzymes that convert arachidonic 
acid (AA) into PGH2, the common intermediate to all PG molecules (Figure 3) (Vane & 
Botting, 1995).  AA is released from the cellular membrane by the action of 
phospholipase A2 (Cha et al., 2006).  Once available, the cyclooxygenase activity of the 
COX enzyme cyclises AA and converts it to PGG2 through the addition of a 15-hydroxyl 
group (van Anholt et al., 2003).  PGG2 is then reduced to PGH2 by the peroxidase 
activity of the enzyme (Vane & Botting, 1995).  It is PGH2 that other prostaglandin 
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peroxidases act upon to produce tissue specific PGs, such as PGI2 (smooth muscle 
control), PGE2 (gastric epithelium, kidney) and PGF2α (reproductive tissues, brain) (Cha 
et al., 2006). 
 With AA being released from the plasma membrane, the enzymes are also 
membrane bound.  COX are membrane bound haemoproteins found in high concentration 
in the endoplasmic reticulum (Vane & Botting, 1995).  COX is oriented towards the 
lumen of the endoplasmic reticulum and integrates into only 1 layer of the plasma 
membrane (Knights et al., 2010).  The homodimers consist of 3 domains; an N-terminal 
epidermal growth factor-like domain, a membrane binding motif and a C-terminal 
enzymatic domain (Knights et al., 2010; Vane & Botting, 1995).  It is thought that the 
growth factor-like domain is responsible for the association of the two enzymatic 
monomers (Knights et al., 2010).   
COX are present in 2 isoforms; COX-1 and COX-2.  COX-1 is the constitutive 
form of the enzyme, responsible for maintaining background PG levels required for 
normal body function (Vane & Botting, 1995).  The inducible form, COX-2, is 
responsible for the production of PGs necessary for the inflammatory response.  COX-2 
can be activated by the presence of cytokines, mitogens or endotoxins (Mitchell et al., 
1994).  In human COX enzymes there is a 60% sequence homology between the two 
isoforms, with each being approximately 70 kD in size (Vane & Botting, 1995).  COX 
enzymes are not only found in mammals, but have also been detected in other vertebrate 
species.  Zou et al. (1999) demonstrated that there were inducible forms of COX present 
in fish species.  Ishikawa and Herschman (2007) elaborated on this point using the 
rainbow trout (Oncorhynchus mykiss) genome and discovered there were actually two 
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different types of inducible COX isoforms; COX-2a and COX-2b.  Depending on the 
species, there is a 65 – 84% DNA sequence homology between fish and human isoforms 
(van Anholt et al., 2003).  For rainbow trout in particular, there is an 83-84% homology 
between COX-1 and 77% homology between COX-2 when compared to human 
cyclooxygenase enzymes (Fent et al., 2006).  This further shows that COX genes are 
conserved across many species and that they perform similar functions to those in 





















Figure 3: Conversion pathway of arachidonic acid to various prostaglandins.  The 
enzymes phospholipase A2, COX and various prostaglandin peroxidases assist in the 





1.6.3 Mode of Action 
 NSAIDs are used as therapeutic agents due to their ability to inhibit COX 
enzymes (Vane & Botting, 1998).  In general, they are racemic mixtures of weak acids 
that either reversibly or irreversibly bind to the active site of the enzymes, rendering them 
inactive (Khetan & Collins, 2007; Santos et al., 2010).  This can be achieved in one of 
three ways.  NSAIDs can inhibit by rapid, competitive reversible binding, such as the 
case of ibuprofen.  They can also use rapid low-affinity binding followed by high-affinity 
time dependent binding, like diclofenac.  Lastly, in the method used by aspirin, they can 
inhibit COX activity by rapid reversible binding followed by covalent modification 
(Knights et al., 2010).  All of these methods are dependent on drug interactions with the 
active site of the enzyme. 
The active site of COX is a long, hydrophobic channel designed to accommodate 
arachidonic acid in the first step of the enzymatic process (Vane & Botting, 1998).  
Within this cavity, the amino acids tyrosine 385 and serine 530 are essential for the 
conversion of AA to PGG2, but these are not the most important residues to consider 
when discussing NSAID inhibition (Vane & Botting, 1998).  The main difference 
between the actives sites of COX-1 and COX-2 is the size of their active sites themselves.  
The active site of COX-2 is larger than that of the other isoform, allowing it to 
accommodate compounds of a larger molecular size (Vane & Botting, 1998).  The 
difference in cavity space of the active site is due to one amino acid substitution in 
particular.  In the active site of COX-2, the larger isoleucine residue at site 523 is 
substituted for a smaller valine (Knights et al., 2010).  The substitution significantly 
opens the active site by forcing the surrounding amino acids into a different configuration 
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(Figure 4).  It is this physical difference that allows for the selectivity amongst the 
pharmaceuticals. 
As Vane theorized during his work with NSAIDs, it is possible to design PPCPs 
preferentially that target one isoform over another (Vane & Botting, 1995).  By creating 
molecules that target only COX-2, some of the negative side effects associated with 
NSAID use may be reduced (Mitchell et al., 1994).  If the COX-2 isoform, responsible 
for the PGs that cause pain and inflammation, is inhibited while the constitutive form 






















Figure 4: Structural configuration of the actives sites of the two COX isoforms. (A) The 
active site of COX-1 has isoleucine at position 523, creating a smaller entrance into the 
cavity whereas (B) COX-2 has valine at position 523, forcing the surrounding amino 
acids into a different configuration, allowing for a wider opening.  This substitution 
allows for the selectivity in NSAIDs, where smaller molecules (ie. ibuprofen) can fit into 
the active sites of both whereas larger molecules (ie. naproxen) cannot.  Figure modified 





 There are numerous OTCs currently on the market that act as COX inhibitors.  
The PPCPs that are most used are ibuprofen and, more recently, naproxen.  Ibuprofen is 
considered a non-selective COX inhibitor since it acts on both COX-1 and COX-2.  
Naproxen, on the other hand, is COX-2 selective (Vane & Botting, 1998).  The ratio of 
inhibition between COX-2/COX-1 is what decides selectivity.  The ratios are calculated 
using IC50 values, defining the concentration at which that particular pharmaceutical 
inhibits 50% of either isoform (Knights et al., 2010).  Naproxen has a larger structure, 
which can fit into the wide active site of COX-2 but not as easily into that of COX-1 
(Figure 4).  The remainder of this discussion, as well as the research undertaken, will 
focus on ibuprofen. 
 Ibuprofen is the NSAID produced in the highest quantity globally, which is in part 
due to the World Health Organization including it as a core medicine on its “Essential 
Drug List” (Han et al., 2010).  Commonly ingested orally, ibuprofen is transported 
through the body via the circulatory system, where up to 99% of the compound is bound 
to plasma albumin (Thomas, 2007).  In addition to being bound to plasma proteins, 
ibuprofen can also be found within tissues at significantly high concentrations.  A 
possible reason for its inclusion on the essential drug list is the fact that ibuprofen is very 
effective.  Although it only possesses a half life of approximately 2 hours, being non-
selective in its COX inhibition allows ibuprofen to prevent symptoms caused by pain and 
inflammation (Thomas, 2007; Vane & Botting, 1998).  Upon excretion, approximately 
10% is still present as the parent compound where the rest is metabolized through Phase I 
and Phase II metabolism (Khetan & Collins, 2007).  It is first oxidized and then 
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conjugated with glucuronic acid prior to excretion (Halling-Sørensen et al., 1998).  While 
this may suggest that only a small percentage of the active compound is entering aquatic 
systems, it is possible for the reconversion of metabolites into the parent compound 
through enzymatic reactions or chemical hydrolysis (Daughton & Ternes, 1999).  With its 
high use worldwide, quick removal rate from the body and the fact that it remains in the 
biologically active compound in water systems makes ibuprofen an ideal NSAID to study 
in relation to toxicity. 
 
1.7 Exposure Techniques 
 When designing toxicity experiments, standardized guidelines are routinely 
consulted, such as those produced by the U.S. EPA (Fent et al., 2006).  While such tests 
are standard procedure, generic guidelines may not be sufficient when evaluating PPCP 
toxicity in aquatic environments.  Mortality is an endpoint commonly used to evaluate 
toxicity but such an endpoint is generally not relevant to pharmaceuticals given their low 
environmental concentrations elicit mainly sub-lethal effects (Fent et al., 2006).  When 
sub-lethal effects have been evaluated, they are mainly based on acute rather than chronic 
exposures. 
 Acute experiments are classified as exposures lasting no longer than 96 hours 
(Huggett et al., 2003).  Although acute tests are commonly performed they are not 
entirely relevant when it comes to determining the safety of PPCPs in aquatic systems.  
This is because acute testing is normally completed using abnormally high chemical 
concentrations that greatly exceed those found in the environment (Huggett et al., 2003).  
Because of this lack of environmental realism, the actual impact of these chemicals to 
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aquatic organisms may be masked by limiting methodologies (Fent et al., 2006).  Another 
issue associated with acute experiments is that the exposure techniques may vary greatly.  
Acute studies have been completed using injections as the exposure route for 
pharmaceuticals.  For example, Hoeger et al. (2008) studied how the NSAID diclofenac 
distributed within the tissues of brown trout (Salmo trutta f. fario) through the use of 
intraperitoneal injections.  While this research is important to build the knowledge base 
on how PPCPs move through tissues, the exposure route may not be environmentally 
relevant. 
 More chronic PPCP exposure studies, a minimum of 1-3 months in length, are 
urgently needed (Huggett et al., 2003).  Aquatic organisms, living near WWTP discharge 
sites, are continuously exposed to PPCPs and other chemicals over their entire lifespans.  
Aquatic toxicological research needs to mimic this occurrence.  Undertaking chronic 
experiments, however, is significantly more difficult, encouraging the use of 
mathematical models to estimate chronic exposure, but such a theoretical approach also 
has its limitations (Fent, 2008).  Ragugnetti et al. (2011) recently conducted a chronic 
exposure using tilapia (Oreochromis miloticus), although the exposure only lasted 10 
days.  One of the longest exposures reported for ibuprofen involved Japanese medaka 
(Oryzias latipes) exposed to waterborne ibuprofen over 6 weeks (Flippin et al., 2006).   
 For chronic toxicity testing, 3 main areas should be considered when designing 
experiments.  First, the target specificity should be determined (Fent, 2008).  The 
researchers should know which specific biomolecules, tissues and organs should be 
analyzed depending on the chemical used.  Second, evaluation of side-effect specificity is 
required (Fent, 2008).  Side effect specificity will consider effects that are expected but 
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since some PPCPs do not have well defined modes of action, physiological mechanisms 
in aquatic organisms may differ from those of humans.  Lastly, species specificity needs 
to be taken into consideration (Fent, 2008).  This last point will cover any general chronic 
effects that account for differences in physiology.  These factors, in combination, provide 
the basis for well designed chronic exposure experiments. 
 
1.8 Biomarkers of PPCP Toxicity in Aquatic Environments 
 Ecotoxicology is based on the study of endpoints which may indicate processes 
leading to disease (Ward & Henderson, 1996).  These endpoints are called biomarkers.  
Specifically, biomarkers can be defined as any measurement of body fluids, cells or 
tissues that indicate biochemical or cellular alterations due to the presence of pollutants 
(van der Oost et al., 2003).  These markers of toxicity can be subdivided into three main 
categories: biomarkers of exposure, biomarkers of effect and biomarkers of susceptibility 
(Ward & Henderson, 1996).  While some biomarkers span categories, the main purpose 
of these endpoints is to determine if potentially harmful chemicals have entered the 
environment and are causing effects (van der Oost et al., 2003; Ward & Henderson, 
1996).  Although these tests have their limitations, such as not taking into consideration 
any physicochemical effects that occur while these chemicals are in the environment that 
may modulate toxicity, they still provide a good representation of the interaction of the 
chemical and the biological system (van der Oost et al., 2003).  For complex research, a 
mixture of different biomarkers should be selected to achieve a greater understanding of 
the processes occurring (Ward & Henderson, 1996). 
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 Fish are commonly used as the test organisms for biomarker research.  Fish are 
found in most aquatic environments and are of ecologic importance.  They play a 
significant role in the energy transfer between lower and higher tropic levels and are an 
important food resource for humans (van der Oost et al., 2003).  While there are 
differences between fish species, which ever species is chosen should have a relationship 
to the chemical or region being tested (van der Oost et al., 2003).  For pharmaceutical 
research in Canada, rainbow trout (Oncorhynchus mykiss) are good test organisms.  Not 
only are they relevant to the Canadian environment, it has been previously discussed how 
trout possess similar enzymatic pathways to humans making them susceptible to PPCPs, 
such as NSAIDs (see section 1.6.2 Prostaglandins and Cyclooxygenase Enzymes). 
 
1.8.1 Condition Factor 
 Condition factor (K) is a parameter widely used to gauge the overall quality of 
fish.  Proposed by Fulton in 1904, K is the relationship between the weight and length of 
a fish (Barnham & Baxter, 1998; Nash et al., 2006).  How ‘fat’ or ‘skinny’ a fish is can 
be made by the visual comparison of its weight to length, whereas K is a mathematical 
representation of the same concept.  The condition factor of a fish can be affected by 
many factors, such as the sex of the fish, the season measured or its developmental stage 
(Barnham & Baxter, 1998).  Using this concept, condition factor can be applied as a 
biomarker for toxicity.  If a chemical was altering the metabolic processes in a fish, its 
weight may significantly decrease.  If a population of trout start out in good health, with 
K values exceeding 1.0, and over the exposure time the K values decrease, this is an 
indicator that the chemical is eliciting a deleterious effect.  Condition factor can be 
29 
 
applied to follow the health of individual fish or to assess fish population health as a 
whole. 
 
1.8.2 Organo-somatic Indices 
 Like condition factor, other indices can be used to determine general health 
qualities of fish, collectively known as organo-somatic indices.  Use of these indices is 
standard practice in fish physiology studies (Schmitt & Dethloff, 2000).  The indices are 
ratios of the weight of individual organs to the total weight of the fish (Schmitt & 
Dethloff, 2000).  Two commonly used are the liver somatic index (LSI) and gonad 
somatic index (GSI).  By measuring LSI and GSI, a view into the overall health of the 
organ system can be determined.  Changes in LSI may represent problems with 
metabolism or energy storage, whereas changes in GSI provide insight into the structural 
conditions (maturity) of the gonads rather than their functionality (Schmitt & Dethloff, 
2000).  It should be noted that numerous factors can also affect these index values so 
their use needs to be evaluated carefully before definitive conclusions are made (Schmitt 
& Dethloff, 2000). 
 
1.8.3 COX Inhibition 
 An in depth discussion about cyclooxygenase and COX inhibition by NSAIDs, 
and how this can be used as biomarkers of toxicity, can be found in 1.6.2 Prostaglandins 





1.8.4 Vitellogenin (VTG) Concentration 
 Vitellogenin (VTG) is an estrogen-dependent yolk protein precursor that is 
synthesized in the liver of non-mammalian female vertebrates (Allner et al., 2000; 
Schmitt & Dethloff, 2000).  In fish, oogenesis is the process by which VTG is produced 
by the liver and taken up by the oocytes (Nicolas, 1999).  More specifically, 
vitellogenesis is the physiological process by which VTG is taken up by the maturing 
oocytes to accumulate yolk (Nicolas, 1999).  This whole process is heavily dependent 
upon hormonal regulation. 
 VTG production is regulated by the hypothalamus-pituitary-gonadal axis.  The 
hypothalamus begins by releasing gonadotropin releasing hormones (GnRH) which will 
act upon the pituitary gland (Nicolas, 1999).  Upon stimulation, the pituitary gland then 
releases gonadotropins (Nicolas, 1999).  Gonadotropins are responsible for regulating the 
functional activity of the gonads as well as promoting reproductive events, such as 
meiosis and ovulation.  When the ovaries are stimulated, they begin to grow and their 
follicles release newly synthesized estradiol (Nicolas, 1999; Sumpter & Jobling, 1995).  
Estradiol enters the blood stream and stimulates the liver to produce VTG (Hansen et al., 
1998; Nicolas, 1999).  Once in the ovary, VTG is then enzymatically cleaved to produce 
the desired yolk proteins, lipovitellin and phosvitin (Schmitt & Dethloff, 2000). 
 For analysis of VTG it should be noted that it is species specific (Hansen et al., 
1998).  Specific antibodies are required for analyzing VTG from differing fish species, 
but what makes it an important biomarker is that its production can be induced by 
external estrogens.  Factors that mimic naturally occurring hormones can cause VTG 
induction in male fish, or female fish that have not yet reached reproductive age (Hansen 
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et al., 1998).  If VTG can be induced in immature female fish this may be a significant 
biomarker in NSAID research.   If natural PG levels are reduced by COX inhibition, 
VTG synthesis may be inhibited even if an external hormone, such as 17-β-estradiol, is 
applied.  Ibuprofen may also have the opposite effect by acting as an estrogenic chemical 
and inducing VTG production.  It is this concept of mixture chemical exposure that will 
help to elucidate pharmaceutical toxicity to non-target aquatic organisms. 
 
1.8.5 Ethoxyresorufin-O-Deethylase (EROD) Activity 
 Another biomarker that may be useful in the determination of how NSAIDs affect 
fish is ethoxyresorufin-O-deethylase (EROD) activity.  In fish studies, it is widely 
accepted to measure EROD activity as an in vivo indicator of CYP1A activity (Schmitt & 
Dethloff, 2000; Whyte et al., 2000). 
 The family of cytochrome P450 (CYP) enzymes are heme-containing proteins 
that play a role in the transformation of lipophilic substances (Carlsson et al., 1999).  
These proteins, which are part of Phase I metabolism reactions, oxidize, hydrolyze or 
reduce compounds to increase their hydrophilicity for excretion (Carlsson et al., 1999; 
Schmitt & Dethloff, 2000).  The enzymes are concentrated mainly in the liver of fish and 
can be located in the smooth endoplasmic reticulum (Schmitt & Dethloff, 2000).  The 
subfamily responsible for these reactions is the CYP1A group.  These enzymes are 
similar in fish as they are in mammals.  In trout, CYP1A1 and CYP1A3 are the enzymes 
responsible for metabolism of xenobiotics chemicals, but for the purposes of this 
discussion they will be grouped as CYP1A (Carlsson et al., 1999). 
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 CYP1A induction is a biomarker of exposure for certain chemicals, such as 
polyaromatic hydrocarbons (PAHs) and similarly structured planar compounds (Schmitt 
& Dethloff, 2000).  Upon exposure, xenobiotic compounds bind to the aryl hydrocarbon 
receptor (AhR) (Whyte et al., 2000).  This receptor is a ligand-activated transcription 
factor.  When bound to a ligand, AhR binds DNA and initiates transcription of specific 
genes, such as those for CYP1A and other enzymes required for Phase II metabolism 
(Whyte et al., 2000).  Therefore, the increased presence of compounds able to activate 
AhR will lead to increased amount and activity of CYP1A. 
 An indirect measure of this is through measuring the activity of EROD.  EROD 
activity is a highly sensitive indicator of contaminant uptake in fish since it is related to 
receptor mediated induction of CYP-dependent monooxygenases (Schmitt & Dethloff, 
2000).  EROD measures the conversion of 7-ethoxyresorufin (7ER) to resorufin, which 
can be measured fluorometrically (Whyte et al., 2000).  When using EROD activity as a 
biomarker, it should be understood that it is a better indicator of exposure rather than 
effect (Schmitt & Dethloff, 2000).  Research is still being done to determine the link 
between CYP1A induction and how this may relate to toxicity within organisms (Whyte 
et al., 2000).  It is believed that increasing CYP1A activity alters the state of homeostasis 
within the cell which can lead to detrimental effects (Schmitt & Dethloff, 2000).  
Measuring EROD activity is useful because it shows that AhR active compounds are 
present, and represents the cumulative impacts of all such chemicals, even if they are 
below measurable detection limits (Schmitt & Dethloff, 2000). 
Care needs to be taken when evaluating EROD activity because it may be 
influenced by abiotic and biotic factors such as water temperature, the age of the test 
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organisms and that organism’s reproductive age (Schmitt & Dethloff, 2000).  Results 
from EROD activity assays need to be evaluated critically to ensure that these external 
factors are not skewing the results obtained.  While some chemicals may increase 
CYP1A activity at one concentration, the same compound may inhibit activity at higher 
concentrations (Whyte et al., 2000).  Also, some chemicals, either in isolation or in 
mixtures, may inhibit EROD activity (Whyte et al., 2000).  While extremely useful, 


































2.0 Purpose of Study 
The purpose of this research was to study the effects of NSAIDs, specifically the 
non-selective COX inhibitor ibuprofen, on rainbow trout (Oncorhynchus mykiss) 
following acute and chronic exposures.  Using a flow-through dose controlled system for 
waterborne exposure, a 96 hour and an 8 week (56 day) experiment were developed to 
help augment the body of literature for this particular PPCP and test organism.  The main 
research goals were to: 
 
(1) Determine if COX activity in rainbow trout was affected following acute and 
chronic ibuprofen exposure and if this activity varied between tissues. 
 
(2) Determine if plasma VTG levels were altered during exposure to ibuprofen and a 
mixture of the hormone 17-β-estradiol (E2) when compared to plasma samples 
from fish exposed to the hormone alone; and 
 











3.1 Test Organisms 
Juvenile female rainbow trout (Oncorhynchus mykiss) weighing approximately 50 
grams were obtained from Linwood Acres Trout Farm Ltd. (Campbellcroft, Canada) on 
May 28th, 2010.  After being transported to the aquatic toxicology wet laboratory at the 
University of Ontario Institute of Technology (UOIT, Oshawa, Ontario, Canada), the fish 
were allowed to acclimate prior to experimentation in 1500 L tanks.  During the 
acclimation period, the fish were fed a ration of 0.4% body weight and the temperature 
was maintained at 12.3 ± 1.2º C and a pH of 7.1 ± 0.4. 
 
3.2 Chemicals and Reagents 
 The chemicals required for exposure and analysis of tissue samples were 
purchased from Sigma Aldrich (Oakville, Canada), Fisher Scientific (Ottawa, Canada) 
and BioShop Canada Inc. (Burlington, Canada).  The exception to this was the polyclonal 
antibody necessary for the vitellogenin enzyme-linked immunosorbent assay (ELISA), 
which was purchased from the Biosense Laboratory (Thormøhlensgt, Norway).  
Individual chemicals were purchased and standard protocols were followed for all 
biomarker assays, except total COX activity.  To complete the COX analysis, COX 
Activity Assay Kits (Catalogue No. 760151) were purchased from the Cayman Chemical 





3.3 Flow-Through Dose Controlled System 
 Before establishing the dose system for experimentation, the peristaltic dose 
pump that was to be used (multi-channel cartridge pump, Watson Marlow Bredel Pumps, 
Massachusetts, USA) was calibrated to ensure that a constant volume of water was 
accurately dispensed.  This was done by setting up a mock system and collecting the 
water that was run through the pump for a 24 hour period at a set speed (rpm) and tube 
diameter.  At the end of the 24 hour period, the volume of water dispensed was weighed 
and the flow rate calibrated to ensure that it matched that specified by the manufacturer.  
Once this was verified, the conditions necessary for each exposure were tested. 
 A constant supply of clean water was provided to each of the exposure tanks.  The 
flow of water was set at 4 turnovers of water each day to achieve 99% molecular renewal 
every 24 hours (Sprague, 1969).  Depending on the flow of water into the tank (2.08 
mL/sec for the acute exposure and 3.24 mL/sec for the chronic exposure) which varied 
due to the different tank volumes used, the dose pump was set to replenish the amount of 
drug lost from the tank each second using the ibuprofen stock solutions prepared.  Stock 
solutions were prepared in concentrations higher than the desired treatment 
concentrations to allow for dilution upon mixing with the clean water entering the tank. 
 Once the system had been calibrated on the bench top, the pump was set up in the 
wet laboratory. Nalgene bottles (1 L) were used to house the stock solutions.  Holes were 
drilled in the lids of the bottles and plastic rods were inserted, coming to rest just above 
the bottom of the bottle (Figure 5a).  Flexible plastic tubing of a set diameter (1.42 mm) 
was connected to the plastic rods, which then were fed through individual channels on the 
peristaltic pump (Figure 5b).  The stock bottles, along with the pump itself, were 
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positioned on a shelf built above the treatment tanks.  The tubing then exited the pump 
and was connected into the water supply tube flowing into each individual tank (Figure 
5c).  This allowed for mixing of the highly concentrated stock solution and clean water 
prior to entering the tank.   
The dose pump was set to deliver a dose of 120 µL/min for the acute exposure 
and 80 µL/min for the chronic exposure.  The dose rate was altered so that the 1 L stock 





















Figure 5: Set up of flow-through dose controlled system. (A) 1 L nalgene stock solution 




3.4 Experimental Design 
3.4.1 Acute Exposure 
 The acute exposure, set at 96 hours, was designed to test if exposure to ibuprofen, 
using concentrations higher than what is found in the environment, could act as an 
endocrine disruptor on juvenile rainbow trout in isolation and in combination with the 
hormone E2.  To do this, 5 different treatments were run in duplicate.  Two different 
ibuprofen concentrations were selected, 10 mg/L and 1 mg/L, along with a control 
containing no drug, a positive control tank containing E2 at a concentration of 1 mg/L 
and a  E2-ibuprofen mixture tank containing the highest ibuprofen treatment, 10 mg/L, 
and 1 mg/L E2. 
 To achieve the desired ibuprofen concentration within the treatment tanks, stock 
solutions were prepared using ibuprofen sodium.  Ibuprofen sodium was used instead of 
ibuprofen in the pure form due to potential solubility issues.  As previously described, the 
stock solutions were prepared at a higher concentration to allow for dilution within the 
tanks.  It should also be noted that the concentrations refer to the amount of anionic 
ibuprofen and not the concentration of the salt.  To achieve a concentration of 10 mg/L 
and 1 mg/L in the treatment tanks, using a flow rate of 120 µL/min, stocks of 10.4 g/L 
and 1.04 g/L ibuprofen were prepared.  These solutions were then placed into the nalgene 
bottles in the dose system.  Each tank had a stock bottle associated with it, even if it did 
not receive a continuous dose of ibuprofen.  The stock bottles associated with the control 




 Seventy litre glass aquaria were used as the exposure tanks but were only filled to 
45 L.  The reduced volume of water was selected due to the fact that only 4 fish were 
being used per treatment, as well as to reduce the amount of ibuprofen required to prepare 
the concentrated stock solutions.  The tanks were filled with clean water to 45 L and the 
dosing system was started.  The initial running of the system before the fish were 
introduced allowed the tanks time to reach the appropriate concentration.  After 24 hours 
had passed, 4 fish were moved from the 1500 L acclimation tanks and placed into each of 
the 10 exposure tanks, which signified the beginning of the experiment.  A total of 44 fish 
were used in the experiment, 4 in each of the 10 treatment tanks plus 4 fish that were 
sampled from the 1500 L acclimation tanks to serve as background levels for all analyses. 
 Unlike ibuprofen which was exposed continuously, a pulse exposure was used for 
E2.  The high cost of the chemical prevented a continuous exposure.  To prepare the E2, 
180 mg was dissolved in 4 mL of acetone.  This allowed 1 mL of the solution to be added 
to each of the four E2 exposure tanks, creating a concentration of 1 mg/L. 
 After the fish had been placed into the treatment tanks, the water system and dose 
pump were turned off, creating a static system for the E2 pulse exposure.  Again, all the 
tanks were treated in the same manner even if they were not receiving a hormone dose.  
A 1 L beaker was used to remove approximately 1 L of water from each of the tanks 
receiving the E2 dose and 1 mL of the E2 solution was added.  This was to allow mixing 
before the water was added back to the treatment tanks.  With the E2 solution added, the 
tanks were kept in a static state for 2.5 hours.  When the flow through system was 
resumed, the concentration of E2 in the tanks slowly decreased over the next 24 hours. 
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 All tanks were vacuumed each morning although the fish were not fed during the 
course of the experiment.  The average temperature of the treatment tanks was 16.3 ± 1.1º 
C with a pH of 7.1 ± 0.4. At the end of the 96 hours, the system was shut off and all the 
fish were sampled. 
 
3.4.2 Chronic Exposure 
 The chronic exposure lasting 8 weeks (56 days) was designed to study the same 
end points as the acute exposure, but completed using concentrations focused around 
those measured in the Canadian environment.  A logarithmic scale was used for the three 
ibuprofen treatment concentrations (1, 32 and 1000 µg/L), along with an experimental 
control, E2 control of 1000 µg/L and an E2-ibuprofen mixed treatment of 1000 µg/L E2 
and 1000 µg/L ibuprofen.  It should be noted that the E2 concentrations, along with one 
of the ibuprofen treatment concentrations, are the same in both the acute and chronic 
exposures (ie. 1 mg/L and 1000 µg/L).  The 6 treatments were run in duplicate, with the 
replicates being staggered by 1 day. 
 To achieve the desired concentrations of ibuprofen in the aquaria, stock solutions 
of 2.43 g/L, 77.78 mg/L and 2.43 mg/L ibuprofen were prepared.  The stock bottle set-up 
was the same as the acute exposure. 
 Prior to the start of the experiment, the fish were acclimated in the full 70 L glass 
aquaria without any drug exposure for 4 days due to the higher density of fish in the 
tanks.  Fifteen fish were placed in each treatment tank to allow for 5 fish to be sampled 
on each sampling time (day 14, day 28 and day 56).  A total of 186 fish were used in the 
experiment, 15 in each of the 10 treatment tanks and 6 fish that were used as background 
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control samples.  At the start of the experiment the dose system was turned on to allow 
the ibuprofen in the tank to gradually increase to the desired concentration. 
 The E2 pulse exposure was also done in the same fashion as the acute experiment.  
On the first day of every week the water and dose system were turned off to allow for a 
2.5 hour static E2 exposure.  Upon completion the water and dose pump were turned 
back on.  This was completed every week for a total of 8 exposures. 
 Each tank was cleaned every morning and the fish were fed a daily ration of 0.4% 
body weight divided into two feedings (morning and afternoon).  The temperature was 
maintained at 13.1 ± 0.6º C over the 8 weeks with a pH of 6.7 ± 0.2. 
 
3.5 Water Sampling 
 While the exposures were occurring, water samples from the treatment tanks were 
taken to determine the actual ibuprofen concentration.  Once during the acute experiment, 
and 4 times during the chronic exposure (weeks 2, 4, 7 and 8) water was removed from 
select treatment tanks using a syringe and filtered directly into a 2 mL ultra performance 
liquid chromatography (UPLC) vial (LCMS certified amber screw top vials, Waters, 
Mississauga, Canada).  A 0.2 µm syringe filter (Puradisc PES filter media, Whatman 
Ltd., Mississauga, Canada) was used to ensure all particulate material was removed from 








 All fish were anesthesized in MS-222 at a concentration of 100 mg/L before 
dissection.  Blood, liver, gonad, kidney, brain and gill samples were collected from all 
fish, with the exception of the gills from the fish used in the chronic exposure 
experiment.  Blood was collected using 4 mL lithium heparin vacutainers (BD, New 
Jersey, USA) and stored on ice until the end of the sampling day.  Tissue samples were 
placed directly in labelled cryovials and flash frozen using liquid nitrogen before being 
stored at -80º C.  After all the fish had been sampled, the blood samples were centrifuged 
at 3000 rpm for 10 minutes and the plasma transferred into 1.5 mL microcentrifuge tubes 
and stored at -80º C. 
 
3.7 Analysis 
3.7.1 Ultra Performance Liquid Chromatography – Mass Spectroscopy 
 Water analysis was performed using an ultra performance liquid chromatography 
– mass spectroscopy system (Waters Acquity UPLC, Micromass Quattro micro API).  
Settings used were based on the information provided in Miao et al. (2002) with a Waters 
Acquity UPLC BEH C18 1.7 µm 2.1 x 100 mm column (Appendix 1).  Calibration 
standards were prepared using the same ibuprofen sodium as in the treatments, diluted 
using Milli-Q water and filtered through 0.45 µm syringe filters.  Integration values 
obtained from the standards were used to prepare calibration curves.  Using these curves 





3.7.2 Condition Factor 
 The condition factor (K) was calculated using the weight of the whole fish and the 
total length based on the equation: 
     K =    Body Weight      x 100 
                  Total Length3  
 
3.7.3 Liver Somatic Index  
 The liver somatic index was calculated based on the relationship between liver 
weight to whole body weight using the equation: 
     LSI =     Liver Weight    x 100 
        Body Weight 
 
3.7.4 Gonad Somatic Index 
 The gonad somatic index (GSI) was calculated based on the relationship between 
gonad weight to whole body weight using the equation: 
     GSI =     Gonad Weight    x 100 
         Body Weight 
 
3.7.5 Cyclooxygenase Activity Assay 
 The total COX activity present in the trout tissue samples were evaluated by 
measuring the peroxidise activity of the COX-1 and COX-2 isoforms on a colourimetric 
substrate.  To complete the COX Activity assay in accordance with the manufacturers’ 
instructions, frozen gill and kidney samples were weighed out to 80 mg and 400 µL of 
Grinding Buffer (0.1 M Tris-HCl, pH 7.8, 1 mM EDTA) was added and homogenized.  
After homogenization, samples were centrifuged at 10 000 g for 15 minutes at 4 º C.  The 
supernatant was collected and stored at -80º C until analysis. 
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 When analysis was to be performed, tissue supernatant samples were removed 
and thawed.  Each sample was divided into two aliquots, one which remained the active 
sample and the other was boiled for 5 minutes to destroy all enzyme activity to produce 
inactive background values.  After boiling, the background samples were centrifuged for 
1 minute at 8 000 g. 
 To prepare the microplate, 120 µL of Assay Buffer (100 mM Tris-HCl, pH 8.0) 
was added to each well, except the COX standard wells where 150 µL were added.  10 
µL of heme, prepared by diluting 88 µL of the provided heme solution with 1912 µL of 
assay buffer, was added to each well.  Forty microliters of the background sample were 
added to the plate in duplicate and 40 µL of the active sample were added to the plate in 
triplicate.  10 µL of the provided COX standard was added to the standard wells.  The 
plate was shaken slightly to mix and incubated at 25º C for 5 minutes.  After the 
incubation period, 20 µL of colourimetric substrate (N,N,N’,N’-tetramethyl-p-
phenylenediamine) was added to each well, along with 20 µL of arachidonic acid, 
prepared by dissolving 100 µL of the provided arachidonic acid solution with 100 µL of 
the provided potassium hydroxide and diluting to 2 mL with Milli-Q water.  After this 
last addition, the plate was slightly shaken to mix, incubated for 5 minutes at 25º C and 
read at 590 nm using a microplate reader (Bio-Tek Synergy HT microplate reader). 
 
3.7.6 Bradford Protein Analysis 
 The assay used to determine total protein concentration in tissue samples is a 
microplate protocol modified from Bradford (1976).  Total protein concentrations were 
determined for all liver and plasma samples using the liver homogenate prepared for the 
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ethoxyresorufin-O-deethylate (EROD) activity assay and the plasma samples for the fish 
vitellogenin enzyme linked immunosorbent assay (ELISA). 
 To begin, a 1 mg/mL solution of bovine serum albumin (> 96%) was prepared by 
dissolving 1 mg in 1 mL of Milli-Q water.  This stock solution was then used to prepare a 
6 point calibration curve (Appendix 2).  The tissue samples were diluted to 1/100 using 
Milli-Q water.  Ten microlitres of each calibration standard and tissue sample were added 
to the microplate in triplicate.  Two hundred twenty five microlitres of Bradford Reagent 
were added to every well and the plate vortexed at 400 rpm for 1 minute.  The plate was 
incubated in the dark for 45 minutes and the absorbance read at 595 nm. 
 
3.7.7 Enzyme Linked Immunosorbent Assay for Fish Vitellogenin 
 The microplate ELISA assay for fish vitellogenin was a 3 day protocol.  On day 1, 
trout plasma samples were allowed to thaw and diluted either 1/1000 or 1/1500 in coating 
buffer (50 mM carbonate/ bicarbonate buffer, pH 9.6) to bring the total protein 
concentration for each sample to approximately 50 µg/mL.  A 7 point calibration curve 
was prepared using the VTG standard and coating buffer (Appendix 3).  Once all the 
standards and samples were prepared, 50 µL of each were added to the plate in triplicate 
and an additional 50 µL of coating buffer were added to the wells. The plate was covered, 
placed in a moistened plastic container and allowed to incubate overnight at 4º C. 
 After the incubation period, the plate was rinsed with a wash solution (Tween-
Phosphate buffered saline, TPBS) and a blocking solution of bovine serum albumin in 
PBS (BSA 2% in PBS) was added to each well in a volume of 100 µL.  The plate was 
then left to incubate at room temperature for 1 hour.  The plate was again washed with 
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TPBS and 50 µL of primary antibody (polyclonal antibody rabbit anti-sea bream PO-2) 
was added to each well and was allowed to incubate overnight at 4º C to ensure binding 
to the VTG proteins. 
 On day 3, the plate was washed with TPBS before 50 µL of secondary antibody 
(secondary antibody peroxidase conjugated sheep anti-IgG Rabbit) was added to each 
well and allowed to incubate for 1 hour to allow the secondary antibody to bind to the 
primary antibody.  During this incubation, the developing solution of 0.04%  O-
phenylenediamine with 0.012% hydrogen peroxide was prepared so 50 µL could be 
added to each well upon completion of the incubation.  Once the developing solution was 
added, the plate was incubated in a humid container at 37º C for 30 minutes.  The 
oxidation of the O-phenylenediamine by the peroxidase enzyme during this incubation 
allowed for the colourimetric reaction to occur.  The reaction was then stopped using 1.8 
M sulfuric acid and the absorbance read at 492 nm. 
 
3.7.8 Ethoxyresorufin-O-Deethylase Activity Assay 
 The protocol used to measure EROD activity in the trout liver samples was 
adapted from Efler et al. (1998).  Prior to analysis, the S9 fraction from the liver tissue 
had to be prepared.  Fifty milligrams of liver tissue was weighed and 250 µL of HEPES 
grinding buffer (pH 7.5) was added and the sample homogenized.  After homogenization, 
the samples were centrifuged at 9000 g for 20 minutes at 4º C.  The supernatant was 
removed, along with the microsomal layer, and was stored at -80º C until analysis. 
 Before the analysis could be completed, a number of reagents were prepared.  A 
resorufin super stock solution was prepared by dissolving 5 mg of resorufin per 1 mL 
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dimethyl sulfoxide (DMSO, > 99.7%).  The resorufin needed to be completely dissolved 
so the solution was allowed to sit on a stir plate for 24 hours to ensure complete mixing.  
This solution was used to prepare a working stock solution by diluting 1 mL of super 
stock in 9 mL of DMSO.  The 7-ethoxyresorufin (7ER) was also prepared in advance.  A 
solution of 0.022 mg/mL 7ER in DMSO was prepared and the absorbance checked to 
ensure it read 1.6 and 1.7 absorbance units.  When the resorufin super stock solution and 
7ER were not being used they were stored at -20º C. 
When the assay was to be completed, the liver samples were removed from the 
freezer and allowed to thaw.  During this time the assay standards were prepared. A 5 
point calibration curve was prepared using the resorufin working solution, further diluted 
in HEPES grinding buffer, and HEPES grinding buffer (Appendix 4).  A solution of 
7ER/HEPES buffer (pH 7.8) was prepared by diluting 550 µL 7ER in 4550 µL HEPES 
buffer.  Once the solutions were prepared 50 µL of the standards and samples were added 
to the plate in triplicate.  Fifty microlitres of 7ER/HEPES was then added to each well on 
the plate.  The plate was placed in darkness and allowed to incubate at room temperature 
for 10 minutes.  During this time a solution of NADPH (β – nicotinamide adenine 
dinucleotide 2’- phosphate reduced tetrasodium salt hydrate, 93.3%) was prepared by 
dissolving 20 mg in 1 mL of Milli-Q water.  Before the end of the 10 minute incubation 
period, the plate was brought to the microplate reader so 10 µL of NADPH could be 
added to each well immediately before the fluorescence of the plate was read.  The plate 
reader was set with an excitation filter of 530 nm (30 nm bandwidth) and an emission 
filter of 590 nm (35 nm bandwidth), and a sensitivity of 25.  Each well of the plate was 
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read once a minute for 15 minutes.  This allowed for the fluorescence units/min (FU/min) 
to be calculated for each sample as well as the slope of resorufin calibration curve. 
 
3.8 Statistical Analysis 
 All statistics were run using Statistica 9.0 (Statsoft, Inc., Oaklahoma, USA).  All 
data sets were checked for normality using Shapiro-Wilks test and homogeneity of 
variance and transformed accordingly prior to running parametric analyses.  All data sets, 
except those from the Bradford protein assay and VTG ELISA for the chronic experiment 
met the requirements for parametric analysis.  All of the data were tested at α ≤ 0.05.  
Data from the acute experiments were analyzed using a 1-way ANOVA and Tukey HSD 
tests.  Data from the chronic experiments, except total plasma protein concentration and 
VTG ELISA data, were analyzed using a factorial ANOVA and Tukey HSD.  For the 
data sets that did not conform to parametric analysis, a Kruskal-Wallis ANOVA was used 
to test individual factors for significance.  If significance was determined, that factor was 
then tested using a Mann-Whitney U test.  All data was then graphed using SigmaPlot 

















 For both the acute and chronic exposure experiments, the results were analyzed 
initially by comparison of the treatments, including the E2 control, to the experimental 
control.  If a significant difference was determined (p ≤ 0.05), an asterisk (*) was denoted 
on the corresponding figure.  Letters were also used to distinguish similarity or 
significant difference between treatments where appropriate. 
 
4.1 Acute Exposure 
 At the conclusion of the exposure, the average fish weight was 76.4 ± 19.5 g. 
 
4.1.1 Water Analysis 
 Water samples were taken from all treatment tanks, measured using UPLC-MS 
and the results pooled (Table 1).  The remainder of this work will reference the nominal 
concentrations. 
 
4.1.2 Mortality Data 
 During the 96 hour exposure, there was a total mortality of 3 fish.  One dead fish 
was found in each of the E2 control (replicate 1), 1 mg/L ibuprofen (replicate 1) and the 
mixed E2-ibuprofen treatment (replicate 1) tanks.  All three fish showed discolouration 
on their caudal fin (Figure 6).  For analysis, it should be noted that all treatments except 










Table 1: Ibuprofen water concentrations from the acute exposure measured using UPLC-
MS. 
Treatment Concentration (mg/L ± SD) 
Control ND* 
E2 Control ND 
Ibu 1 mg/L 1.23 ± 0.02 
Ibu 10 mg/L 4.66 ± 0.17 
Mixed**  4.87 ± 0.43 
*ND = Not Detected 


















Figure 6: Mortality from the acute ibuprofen exposure experiment (mixed E2-ibuprofen 










4.1.3 K, GSI, LSI 
 The condition factor showed that the fish used were in good condition upon 
completion of the experiment. The K values for all treatments were close to, or over 1.0  
(Appendix 5).  There was also no difference between fish in the various treatment tanks 
and controls based on GSI (Appendix 6). 
There were significant differences in LSI found between the treatments and 
control (Figure 7).  The LSI for the E2 control and the E2-ibuprofen mixed treatment 
were significantly higher than the control, while the two ibuprofen treatments did not 














































Figure 7: Liver somatic index (LSI) from the acute ibuprofen exposure experiment.  Bars 
represent mean ± SD. * denotes statistically significant difference (p ≤ 0.05) with respect 
to the control treatment.  n=8 for all treatments except E2 control, Ibu 1 mg/L and mixed 








4.1.4 Total COX Activity 
 Total COX activity was measured in the gill, as well as the kidney, for all fish in 
the acute experiment.  This was due to the availability and condition of the samples, as 
well as the lack of relevant COX activity data for these tissues present in the literature.  
When looking at the gill, there were no significant differences as compared to the control 
(Figure 8a).  While the control was similar to all of the treatments, there were other 
variations detected.  The COX activity of the E2 control was significantly higher than the 
E2-ibuprofen mixed treatment.  This was the only difference, with both ibuprofen 
treatments being similar to all of the other experimental groups. 
 Similar trends were observed when analyzing the kidney data.  Again, the control 
was not different from any of the treatment groups, with one difference being detected 
amongst treatments.  Kidney COX activity in the E2 control and 1 mg/L ibuprofen 
treatment were significantly different, with the E2 control having lower COX activity 
(Figure 8b). 
 When the tissues were compared in terms of treatment, the only difference 







































































Figure 8: Total COX activity measured from the (A) gill and (B) kidney tissue from the acute 
ibuprofen exposure experiment.  Bars represent mean ± SD.  Different letters denote treatments 
belonging to groups with statistically significant difference (p ≤ 0.05).  n=8 for all treatments 




































Figure 9: Comparison of the total COX activity between the gill and kidney tissue from 
the acute ibuprofen exposure experiment. Bars represent mean ± SD.  Different letters 
denote statistically significant difference between tissues within a treatment (p ≤ 0.05).  
n=8 for all treatments except E2 control, Ibu 1 mg/L and mixed 1 mg/L E2 + 10 mg/L Ibu 





4.1.5 Total Plasma Protein & VTG Concentrations 
 Blood samples were collected from all fish except those in the 1 mg/L ibuprofen 
exposure so total plasma protein concentrations and VTG concentrations were not 
measured for that treatment.  After the 96 hour exposure, there were no significant 
differences in total plasma protein concentration between any of the treatments and the 
controls (Figure 10).   
The VTG concentrations between the treatments were similar to one another and 
there were no significant differences in VTG between treatment groups (Figure 11).   
 
4.1.6 EROD Activity 
 There were no significant differences in EROD between any treatments, possibly 



























































Figure 10: Total plasma protein concentrations from the acute ibuprofen exposure 
experiment.  Bars represent mean ± SD.  n=8 for all treatments except E2 control and 














































Figure 11: Vitellogenin (VTG) concentrations from the acute ibuprofen exposure 
experiment. Bars represent mean ± SD.  n=8 for all treatments except E2 control and 


















































Figure 12: Liver ethoxyresorufin-O-deethylase (EROD) activity data from the acute 
ibuprofen exposure experiment.  Bars represent mean ± SD.  n=8 for all treatments except 











4.2 Chronic Exposure 
 Average fish weight was 89.9 ± 31.4 g upon completion of the 56 day chronic 
exposure.  This value did not vary greatly over the 3 sampling periods, with the average 
weights for sampling times 1, 2 and 3 being 84.8 ± 30.0 g, 95.6 ± 30.9 g and 89.7 ± 33.5 
g, respectively. 
 
4.2.1 Water Analysis 
 Water samples were taken from a subset of the exposure tanks from both 
replicates.  Samples were collected and analyzed from the control, 1000 µg/L ibuprofen 
exposure and mixed E2-ibuprofen treatments (Table 2). 
 
4.2.2 Mortality Data 
 During the chronic 8 week exposure, there was a combined experimental 
mortality of 17 fish (Table 3).  No mortality was experienced in any of the control, E2 
control or 1 µg/L ibuprofen treatments.  The greatest mortality occurred in the mixed E2-
ibuprofen treatment, with each tank experiencing a mortality of 5 fish.  Deaths were first 
observed during week 2 and continued for the remainder of the experiment. 
 In addition to recording mortality, fish that died were individually checked for 
physical damage.  Jaw damage was observed in most dead fish, initially seen on day 30 
and which progressed for the remainder of the experiment (Table 3). Beginning as just 
abrasions around the mouth of the fish, damage advanced to deterioration of the complete 
lower jaw (Figure 13).  It should be noted that only dead fish were examined for this 
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damage.  Other fish in the treatment tanks may have displayed this tissue degradation but 
if they survived to the sampling periods they were not included with this data. 
 Due to the significant experimental mortality that occurred, especially near the 
completion of the experiment, the number of fish in each treatment needed to be 
considered when evaluating the data.  For all analyses, replicates were pooled, allowing 
for a maximum of 10 fish to be included for each treatment at each time period.  The 
control, E2 control and 1 µg/L ibuprofen treatments had no mortality and n = 10 for each 
sampling period while other treatments had reduced sample numbers (Table 4).  These 



















Table 2: Ibuprofen water concentrations from the chronic exposure from select 
treatments measured using UPLC-MS. 
Treatment 
Concentrations per Sampling Time (µg/L) 
Ave ± SD 
Week 2 Week 4 Week 7 Week 8 
Rep – 1      
Control ND* ND ND ND ND 
Ibu 1000 µg/L 1030 973 1170 1120 1070 ± 89 
Mixed** 979 993 1110 1100 1040 ± 70 
Rep – 2      
Control ND ND ND ND ND 
Ibu 1000 µg/L 984 1010 1120 1110 1060 ± 71 
Mixed 909 984 1080 1150 1030 ± 108 
Combined      
Control --- --- --- --- ND 
Ibu 1000 µg/L  --- --- --- --- 1060 ± 75 
Mixed --- --- --- --- 1040 ± 84 
*ND = Not Detected 













# Deaths # Fish with Jaw Damage* 
Replicate 1 Replicate 1 Replicate 1 Replicate 2 
Control 0 0 0 0 
E2 Control 0 0 0 0 
Ibu 1 µg/L 0 0 0 0 
Ibu 32 µg/L 1 4 0 3 
Ibu 1000 µg/L 1 1 1 0 
Mixed** 5 5 3 4 
*Refers only to observations made on fish that died during the course of the exposure and 
not those that were sampled. 












Figure 13: Jaw damage observed during the chronic exposure. (A) initial damage 





Table 4: Number of fish sampled for each treatment during each sampling period for the 
chronic exposure experiment. 
Treatment 
Number of Samples per Treatment 
Replicate 1 Replicate 2 Total 
Day 14    
Control 5 5 10 
E2 Control 5 5 10 
Ibu 1 µg/L 5 5 10 
Ibu 32 µg/L 5 5 10 
Ibu 1000 µg/L 5 4 9 
Mixed* 4 5 9 
Day 28    
Control 5 5 10 
E2 Control 5 5 10 
Ibu 1 µg/L 5 5 10 
Ibu 32 µg/L 5 4 9 
Ibu 1000 µg/L 5 6 11 
Mixed 3 5 8 
Day 56    
Control 5 5 10 
E2 Control 5 5 10 
Ibu 1 µg/L 5 5 10 
Ibu 32 µg/L 4 2 6 
Ibu 1000 µg/L 3 5 8 
Mixed 2 1 3 






4.2.3 K, GSI, LSI 
Over the 56 day experimental exposure, none of the treatments showed significant 
difference in condition factor (K) from the control, each other or between sampling 
periods (Appendix 7).  All of the treatments, at all of the sampling times, had values close 
to 1.0. 
The same trend was observed with the gonad somatic index (GSI).  None of the 
treatments varied significantly from the control at each sampling period.  When 
combined for the whole experiment, again, no differences were observed (Appendix 8). 
Similar to the results found in the acute exposure, differences were detected in the 
liver somatic index (LSI) (Figure 14).  Overall, there were significant differences in LSI 
between treatments.  While the LSI for all three ibuprofen exposures were similar to the 
control, they varied from one another.  The 1 µg/L treatment LSI was significantly lower 
than the LSI for the 1000 µg/L treatment.  Also, the E2 control and mixed E2-ibuprofen 
treatment LSIs were different from all other treatments, including the control, and to one 
another.  The mixed E2-ibuprofen treatment had a higher LSI value than the E2 control.   
To see the trends clearly, the data were broken into their respective sampling 
times (Figure 15).  On Day 14, the E2 control and the mixed treatment LSIs were 
significantly greater than the control LSI.  Although differing from the control treatment, 
the two were similar to the 1000 µg/L ibuprofen treatment LSI.  Across the remaining 
sampling times, day 28 and day 56, the E2 control and mixed E2-ibuprofen treatment 





















































Figure 14: Complete LSI data from the chronic ibuprofen exposure experiment. Data 
from all 3 sampling periods (day 14, 28, 56) have been pooled.  Bars represent mean ± 
SD.  Different letters denote statistically significant difference between treatments (p ≤ 
0.05). n=30 for all treatments except Ibu 32 µg/L (n=25), Ibu 1000 µg/L (n=28) and 
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Figure 15: LSI data from the chronic ibuprofen exposure broken down by sampling time.   
Bars represent mean ± SE. * denotes statistically significant difference (p ≤ 0.05) with 
respect to the control treatment.  Letters denote similarity between groups.  n=10 for all 
treatments except 32 µg/L (n=10, n=9, n=6), 1000 µg/L (n=9, n=11, n=8) and mixed 




4.2.4 Total COX Activity 
 Unlike the acute exposure experiment, total COX activity in the chronic exposure 
experiment was only measured in kidney tissue of the fish because of the availability and 
condition of the tissue.  Also, only a subset was analyzed.  The control, E2 control, 1000 
µg/L ibuprofen and E2-ibuprofen mixed treatments were assayed over the 3 sampling 
periods.  When all the data was combined, there were no differences between the mean 
COX activity values for any of the treatments, with the only difference being reduced 
error associated with the ibuprofen exposures (Figure 16).  No statistical significance was 
detected in COX activity between any of the treatments and control for the 3 sampling 
periods (Figure 17).  Although no difference was determined, biological significance may 
have been overshadowed by variation in the control groups.  An issue arose due to the 
average COX activity in the control group decreasing between day 14 and day 56. 
 To control for changing control values over time, the COX activity for each 
treatment was graphed as a fold of the control for each respective sampling period 
(Figure 18).  Ibuprofen treatments on day 14 showed approximately 25% inhibition of 
activity compared to the control.  Two weeks later, the activity increased to levels similar 
to the control but by day 56 the activity was almost 50% greater than controls.  Similarly, 
the E2 control, 1000 µg/L ibuprofen and mixed E2-ibuprofen treatments from the first 
sampling period were significantly different from the E2 control and ibuprofen treatments 


































Figure 16: Complete kidney COX activity data from the chronic ibuprofen exposure 
experiment.  Data from all 3 sampling periods (day 14, 28, 56) have been pooled.  Bars 
represent mean ± SD.  n=30 for all treatments except Ibu 32 µg/L (n=25), Ibu 1000 µg/L 










































Figure 17: Kidney COX activity data from the chronic ibuprofen exposure broken down 
by sampling time.   Bars represent mean ± SE.  Different letters denote statistically 
significant difference between groups (p ≤ 0.05).  n=10 for all treatments except 32 µg/L 
(n=10, n=9, n=6), 1000 µg/L (n=9, n=11, n=8) and mixed 1000 µg/L E2 + 1000 µg/L Ibu 



















































Figure 18: Kidney COX activity data from the chronic ibuprofen exposure broken down 
by sampling time and represented as fold of control.  Bars represent mean ± SE.  
Different letters denote statistically significant difference between groups (p ≤ 0.05).  
n=10 for all treatments except 32 µg/L (n=10, n=9, n=6), 1000 µg/L (n=9, n=11, n=8) 
and mixed 1000 µg/L E2 + 1000 µg/L Ibu (n=9, n=8, n=3) treatments for day 14, day 28 




4.2.5 Total Plasma Protein & VTG Concentrations 
 Overall, the E2 control and mixed E2-ibuprofen treatments had significantly 
higher total plasma protein concentrations over the course of the entire chronic 
experiment (Figure 19).  When sampling periods are analyzed separately, it can be seen 
that the two treatments were consistently different from the controls and remaining 
treatments over each time point (Figure 20).   
 The results of the VTG ELISAs mimic that of the total plasma protein 
concentration.  When the entire experiment is analyzed, three treatments show significant 
difference in VTG concentration.  The E2 control, the 1000 µg/L ibuprofen and mixed 
E2-ibuprofen treatments had significantly higher VTG relative to the controls (Figure 
21).  This relationship was clarified when the data were analyzed by sampling time.  
While the E2 control and mixed E2-ibuprofen treatment have VTG concentrations that 
were significantly higher than the controls, some of the other ibuprofen exposures also 
varied (Figure 22).  On day 14, the 1000 µg/L ibuprofen treatment VTG concentration 
was significantly lower than the control.  On day 28, this treatment was no longer 
different while the 1 µg/L treatment was significantly lower than controls.  By the last 
sampling period on day 56, every treatment had VTG concentrations that were 




























































Figure 19: Complete plasma protein concentration from the chronic ibuprofen exposure 
experiment.  Data from all 3 sampling periods (day 14, 28, 56) have been pooled.  Bars 
represent mean ± SD. * denotes statistically significant difference (p ≤ 0.05) with respect 
to the control treatment.  n=30 for all treatments except Ibu 32 µg/L (n=25), Ibu 1000 
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Figure 20: Plasma protein concentrations from the chronic ibuprofen exposure broken 
down by sampling time.   Bars represent mean ± SE. * denotes statistically significant 
difference (p ≤ 0.05) with respect to the control treatment.  n=10 for all treatments except 
32 µg/L (n=10, n=9, n=6), 1000 µg/L (n=9, n=11, n=8) and mixed 1000 µg/L E2 + 1000 






















































Figure 21: Complete VTG concentrations from the chronic ibuprofen exposure 
experiment.  Data from all 3 sampling periods (day 14, 28, 56) have been pooled.  Bars 
represent mean ± SD. * denotes statistically significant difference (p ≤ 0.05) with respect 
to the control treatment.  n=30 for all treatments except Ibu 32 µg/L (n=25), Ibu 1000 
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Figure 22: VTG concentration data from chronic ibuprofen exposure broken down by 
sampling time.   Bars represent mean ± SE. * denotes statistically significant difference 
(p ≤ 0.05) with respect to the control treatment.  n=10 for all treatments except 32 µg/L 
(n=10, n=9, n=6), 1000 µg/L (n=9, n=11, n=8) and mixed 1000 µg/L E2 + 1000 µg/L Ibu 





4.2.6 EROD Activity 
 EROD activity over the entire experiment in every treatment except the 32 µg/L 
ibuprofen exposure was significantly lower than the control (Figure 23).  Analysis by 
sampling period, however, revealed temporal differences (Figure 24).  On day 14, the 1 
µg/L ibuprofen treatment was the only group with significantly lower EROD activity 
than controls. By day 28, the EROD activity of the lowest ibuprofen treatment had 
increased whereas the activity of the highest exposure, 1000 µg/L ibuprofen, was now 
significantly reduced relative to controls.  By day 56, two groups showed significant 
reduction in EROD activity; the E2 control and the E2-ibuprofen mixed treatment.  The 
mixed E2-ibuprofen treatment EROD activity was also significantly lower than EROD 






































































Figure 23: Complete EROD activity data from the chronic ibuprofen exposure 
experiment.  Data from all 3 sampling periods (day 14, 28, 56) have been pooled.  Bars 
represent mean ± SD. Different letters denote statistically significant difference between 
groups (p ≤ 0.05).   n=30 for all treatments except Ibu 32 µg/L (n=25), Ibu 1000 µg/L 
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Figure 24: EROD activity data from chronic ibuprofen exposure broken down by 
sampling time.   Bars represent mean ± SE. * denotes statistically significant difference 
(p ≤ 0.05) with respect to the control treatment. Different letters denote statistically 
significant difference between groups (p ≤ 0.05).   n=10 for all treatments except 32 µg/L 
(n=10, n=9, n=6), 1000 µg/L (n=9, n=11, n=8) and mixed 1000 µg/L E2 + 1000 µg/L Ibu  







 Mortality occurred during both the acute and chronic ibuprofen exposure 
experiments.  The dead fish observed were distinct due to the apparent physical 
differences.  During the 96 hour exposure experiment, the fish that died had 
discolouration of their caudal region.  One reason for this may be stress.  The fish were 
held prior to experimentation in 1500 L circular tanks and were moved to 70 L tanks, 
filled to 45 L, without acclimation.  This stress to the fish may have resulted from the 
change in tank conditions.  In circular tanks, water enters tangentially, which not only 
creates a current for the fish to swim against but also results in homogeneous water 
conditions (Oca & Masaló, 2007).  This allows water parameters, such as dissolved 
oxygen content, to be uniform throughout the entire tank.  Also, the water current aids in 
self-cleaning of the tank, forcing the solid material into the center outflow pipe (Oca & 
Masaló, 2007).  Moving from the stable conditions of the large holding tanks to the 
smaller experimental aquaria would likely increase the stress levels of the fish.  In the 
glass exposure tanks, the low flow and rectangular aquarium shape does not allow for a 
current to be created.  However, while low flow could have formed stagnant areas, the 
presence of an air stone in the tanks helped maintain oxygen levels as well as circulate 
water.   
Another possible reason for the observed colour change was physical trauma.  A 
loss of scales may account for the apparent ‘white colour’ in the caudal region.  With 
nothing abrasive in the exposure aquaria except the air stones, which were covered, the 
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damage was probably caused by other fish.  In both nature and the laboratory, salmonid 
fish form dominance hierarchies (Gilmour et al., 2005).  Fish are able to assume 
dominant positions over other more subordinate fish through antagonistic interactions 
(Gilmour et al., 2005).  This generally occurs through aggression (Gilmour et al., 2005).  
Confined to smaller experimental tanks the subordinate fish would have nowhere to 
escape the aggression of the dominant fish.  Chasing and fin nipping may cause a loss of 
scales, producing the light colour.  The lack of feeding during the 96 hour exposure may 
have also increased this activity. 
A combination of these factors may have lead to the discolouration observed on 
the fish that died during the acute exposure.  It is assumed that the fish that died were the 
subordinate fish in the tank that became weakened due to aggression asserted by the 
dominant fish.  To reduce the possibility of this occurring in future experiments, fish 
should be fed to satiation prior to being placed in the experimental tanks and an 
acclimation period should occur prior to the start of the exposure.  The use of smaller fish 
would have also reduced stress levels significantly. 
The acute experiment was run before the chronic exposure, which allowed for 
experimental design changes to be made.  In the chronic exposure the fish were allowed 
to acclimate in the treatment tanks before the exposure began.  This allowed the fish to 
become accustomed to their new environment, presumably reducing stress.  Although 
dominance did occur in the tanks due to the increased number of fish (n = 15), the fish 
were fed twice daily and the density was reduced with each sampling period.  While the 
overall conditions were improved compared to the acute exposure, mortality was 
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significantly higher in the ibuprofen and mixed treatments, likely due to the long 
exposure period. 
While some of the mortality experienced can be attributed to the reasons already 
outlined for the acute experiment, such as aggression, the physical damage observed 
requires further explanation.  A large number of the dead fish showed significant jaw 
damage.  The jaw damage observed in the two highest ibuprofen treatments (32 µg/L and 
1000 µg/L ibuprofen), as well as the mixed E2-ibuprofen treatment, may be a treatment 
effect.   
Prostaglandins play a crucial role in the complex regulatory network of 
inflammation and tissue damage (Tilley et al., 2001).  Not only do they act to promote 
inflammation and initiate the healing process, they also play a role in the termination of 
the inflammatory response (Tilley et al., 2001).  With this knowledge studies began to 
focus on the effectiveness of wound healing in the presence of reduced PG levels caused 
by NSAID exposure.  Using mouse epithelium as a model system, Müller-Decker et al. 
(2002) showed that exposure to NSAIDs did not retard normal skin healing.  Mice fed an 
oral diet of selective and non-selective COX inhibitors did not show a difference in 
incision wound healing compared to the controls (Müller-Decker et al., 2002).  Other 
studies, however, have demonstrated that the regenerative properties of different tissues, 
such as cartilage and muscle, can be affected upon NSAID use (Bondesen et al., 2004; 
Chang et al., 2006).  Using epiphyseal-articular cartilage obtained from fetal rats, Chang 
et al. (2006) found that NSAIDs altered the activity of chondrocytes, critical for cartilage 
maintenance and bone repair.  It was discovered that at therapeutic concentrations the 
pharmaceuticals inhibited thymidine incorporation, arresting the cell cycle (Chang et al., 
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2006).  This suppressed proliferation and induced cellular death, but it should be noted 
that COX-2 selective NSAIDs demonstrated non-significant effects on cytotoxicity 
(Chang et al., 2006).  In addition to structural tissue, Bondesen et al. (2004) investigated 
the role of PGs in myogenesis.  Using mice chronically treated with potent NSAIDs 
specific for COX-1 and COX-2 they determined that following a localized freeze injury 
COX-2 was crucial for muscle regeneration.  By following myofiber regeneration for up 
to 5 weeks post injury, the group determined that PGs produced from the COX-2 isoform 
were essential during the early stages of muscle regeneration (Bondesen et al., 2004).   
Although these pathways are still not well defined, it is understood that 
inflammation is necessary for repair.  Inflammation causes fluid exudation, bringing 
cellular agents to the site to act in tissue repair, which is modulated by PGs (Tilley et al., 
2001).  With chronic exposure to ibuprofen, the inflammatory response in the exposed 
fish may have been inhibited or completely prevented.  If the fish were damaged through 
aggressive behaviours that were taking place in the tank, the lack of PGs in their system 
may have caused the small facial damage to progress into the large wounds where muscle 
and cartilage damage was apparent.  To the best of the author’s knowledge this kind of 
tissue damage in relation to ibuprofen exposure has not been documented previously in 
rainbow trout and further research into wound healing in aquatic organisms exposed to 
NSAIDs needs to occur. 
 
5.2 K, GSI, LSI 
All of the fish from each treatment in both of the experiments had condition factor 
(K) values close to, or over 1.  While according to some scaling guidelines these fish 
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might be considered in ‘fair’ or ‘poor’ condition, this endpoint indicated that overall 
population health did not vary significantly during the course of the experiments 
(Barnham & Baxter, 1998).  The general condition of each fish did not significantly 
improve nor decrease, showing that conditions were stable.  The fish were not fed to 
satiation so their weight should not have increased as compared to length.  Also, the fish 
were not on a starvation ration so they should not have lost weight compared to their 
length.  While condition factor does not provide a great deal of information on the effects 
of acute and chronic ibuprofen exposure, by remaining constant throughout the 
experiment it removed one potential confounding factor. 
 Like condition factor, gonad somatic index (GSI) did not show any significant 
changes over the exposure periods.  No changes were anticipated during the acute 
experiment because although some treatments were dosed with E2, 96 hours was not 
sufficient to see such changes at an organ level.  Changes in GSI, however were expected 
during the chronic ibuprofen experiment due to the increased exposure period.  Although 
the fish used were sexually immature, the hormone treatment may have initiated 
development of the gonads.   
One potential reason for this not occurring was the nature of the exposure.  The 
fish were not treated with the hormone continuously.  Although exposed for 8 weeks, the 
fish were only exposed to E2 on the first day of every week.  This concentration of E2 
was sufficient to increase plasma protein concentrations, such as VTG, but may not have 
been enough to alter the gonad itself.  Werner et al. (2003) continuously exposed 
immature lake trout to various concentrations of the hormone 17-α-ethynylestradiol, 
ranging from 4 ng/L to 400 ng/L for 21 days.  They found a significant increase in GSI 
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for all of the treatment groups (Werner et al., 2003).  In the present study, E2 was added 
to the water at a concentration of 1 mg/L so changes should have been observed if the 
fish were continually exposed.  In future studies, the concentration of E2 used in a 
waterborne exposure could be reduced from 1 mg/L to allow for the continual addition of 
the hormone to the treatment tanks. 
 Both experiments showed differences between treatments with respect to liver 
somatic index (LSI).  Elevated LSIs indicate a large liver relative to the overall body 
weight.  There are many factors that can affect liver weight in fish.  Change in liver size 
is most often associated with toxicant exposure (Schmitt & Dethloff, 2000).  Research 
has demonstrated increased levels of xenobiotic detoxification caused increased size 
rather than increased amounts of detoxification enzymes present including the class of 
CYP1A enzymes (Schmitt & Dethloff, 2000).  In contrast, other work has shown that 
liver size can decrease when exposed to certain types of chemicals (Schmitt & Dethloff, 
2000).   
In the acute exposure experiment, the E2 control and mixed E2-ibuprofen 
treatment had LSI values that were significantly higher than the control group.  The 
chronic experiment also displayed a significant increase in LSI of those two treatments 
compared to the control group.  In the chronic experiment, the mixed E2-ibuprofen 
treatment had a significantly higher LSI than the LSI of the E2 control group overall.  
This may be misleading because when the data were separated into sampling times, the 
treatments did not differ from each other at any of the time points.  The E2-ibuprofen 
mixed treatment LSI on day 56 was the largest of any treatment but only had n = 3 due to 
mortality, so the small sample size may have skewed the analysis. 
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There are few reasons to explain the increase in LSI observed.  One reason is the 
presence of E2.  With the addition of the hormone the immature female trout would begin 
sexual maturation processes, such as vitellogenesis (Schmitt & Dethloff, 2000).  The liver 
in fish undergoing vitellogenesis increases in size due to the production of VTG (Werner 
et al., 2003).  This correlates with the results of the VTG ELISA data from the chronic 
exposure.  Even though no change in VTG was detected in the acute exposure 
experiment, the process of VTG production may have been initiated in the liver, with the 
duration of exposure not being long enough for the concentrations in the blood to be at 
measurable levels.  As mentioned previously, liver size can increase due to detoxification 
processes, so ibuprofen exposure may have contributed to the increase in LSI.   
Flippin et al. (2007) exposed Japanese medaka (Oryzias latipes) to ibuprofen for 
21 days and calculated the LSI.  They found that there was no change in LSI from the 
control in the ibuprofen exposure treatments, but did state that the trend for females was 
to have increased LSI (Flippin et al., 2007).  Parrott and Bennie (2009) conducted a life 
cycle study utilizing fathead minnows (Pimephales promelas) exposed to a mixture of 
pharmaceuticals, including ibuprofen, and also did not find a significant change in LSI.  
From these findings it can be said that the increase in LSI observed in both the acute and 
chronic experiment was likely the result of the hormone treatment initiating 
vitellogenesis and not from the liver detoxification of ibuprofen. 
 
5.3 COX Activity 
 There was no inhibition of total COX activity measured in either the acute or 
chronic ibuprofen experiments.  The results from the 96 hour exposure showed no 
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significant difference in COX activity between any of the treatments and the control 
group for gill or kidney tissue.  The only difference observed was the E2 control in the 
gill had a higher activity than the mixed E2-ibuprofen treatment, whereas the E2 control 
had a lower COX activity than the 1 mg/L ibuprofen treatment in the kidney tissue.  
When the tissues were compared, this difference in the E2 control was the only 
significant variation detected.   
Research conducted by Akarasereenont et al. (2000) using human endothelial 
tissue demonstrated that 17-β-estradiol can alter COX activity.  By dosing the tissue with 
E2, they showed that there was an increase in 6-keto-PGF1α production caused by the 
increased activity of COX-2 (Akarasereenont et al., 2000).  In addition to humans, E2 
was also proven to modify COX-2 activity in rat oviduct tissue when the rats were 
injected with the hormone (Pérez Martínez et al., 2006).  This trend was not apparent in 
this study.  In gill tissue, there was a significant difference in trout COX activity between 
the two treatments that were exposed to E2.  The reason for this difference may be that 
the ibuprofen present in the mixed E2-ibuprofen treatment inhibited the COX activity 
induced by the hormone.  This cannot be definitively stated though because although 
COX activity differed between treatments, there was no difference in activity from the 
controls.  Also, there was no sign of this trend in COX activity in kidney tissue so no 
definitive conclusions can be made. 
 When analyzing the overall COX activity for the chronic exposure even less 
difference was seen between the tissues.  There was no difference between the mean 
COX activities for any of the treatments measured.  Although ibuprofen is a well studied 
COX inhibitor, other published works have commented on the lack of inhibition observed 
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in fish.  Cavallaro and Burnside (1988) studied the effect of PGs on retinomotor 
movement in teleosts to see if reduced PG levels could affect these motor functions. Fish 
were treated with a number of COX inhibitors, including ibuprofen and it was found that 
while the potent COX inhibitor indomethacin reduced COX enzyme activity, ibuprofen 
showed no effects (Cavallaro & Burnside, 1988).   
This was recently corroborated by Lister and van der Kraak (2008).  Using 
zebrafish (Danio rerio) to elucidate the role of PGs on oocyte maturation and ovulation, 
they observed no change in COX activity when the fish were exposed to the NSAID 
indomethacin up to 100 µg/L for 16 days (Lister & van der Kraak, 2008).  COX activity 
in ovary and whole body homogenates showed no changes (Lister and van der Kraak, 
2008).  However, levels of PGE2 were significantly lower and no reasons were provided 
for this observation (Lister and van der Kraak, 2008).   
Similarly, Flippin et al. (2007) exposed Japanese medaka to ibuprofen for 6 
weeks at environmentally relevant concentrations and measured liver COX activity.  
They observed high variability in the COX activity in the controls and reduced variability 
was the primary effect of the ibuprofen exposure (Flippin et al., 2007).  This effect was 
found in overall COX activity in the present chronic exposure experiment.  Both 
measured treatments, 1000 µg/L ibuprofen and mixed E2-ibuprofen, had reduced 
variability in COX activity relative to the controls.  Control variability in COX activity 
was large likely due to changing activity over the 8 week experiment.  From day 14 to 
day 56, total COX activity in the control decreased significantly.  When plotted as fold of 
control to remove this effect, COX activity continually increased from day 14 to day 56 
for the E2 control, 1000 µg/L and E2-ibuprofen mixed treatments.   
92 
 
COX activity in trout did not appear to be inhibited by ibuprofen exposure, 
however, it is possible that inhibition occurred prior to sampling since even for the acute 
exposure, the first sampling did not occur until 96 hours.  Since later time periods were 
analyzed (day 28 and day 56) and no inhibition was found, one possible outcome was that 
inhibition occurred before 96 hours.  With the longer exposure, the fish may have 
recovered their COX activity.  The fish may also have increased ibuprofen metabolism to 
lessen its effects, or the tissues may have increased synthesis of the COX enzymes in an 
attempt to counteract reduced PG levels (Flippin et al., 2007).  Another possible 
explanation may be that the natural variation in COX activity hides any inhibition that 
may have occurred (Flippin et al., 2007).  If the activity between samples varies naturally 
by a significant amount, even if the activity in one particular sample was reduced, the 
reduced activity of another sample may differ so much that the effect is lost in the overall 
variability of the treatment.   
To definitively determine if ibuprofen inhibits COX activity in rainbow trout, 
more research needs to be completed.  Acute studies, with more sampling times and 
higher sample sizes may show that ibuprofen inhibits COX activity but only in a limited 
time window. 
 
5.4 VTG Concentration 
Acute ibuprofen exposure showed no change in total plasma protein 
concentrations, and subsequently, VTG concentrations.  It should be noted that the total 
plasma protein concentration and VTG concentration are linked.  Each plasma sample 
was diluted accordingly to bring the total protein concentration within the optimal range 
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for the ELISA to be run.  Samples with higher total protein concentrations had higher 
VTG levels.  In the acute exposure experiment, no measurable VTG concentrations were 
expected.  Although vitellogenin is known to be induced by external estrogens such as 
E2, 96 hours of waterborne hormone exposure is not sufficient time to induce its 
production (Hansen et al., 1998).  E2 treatments involved exposure to 1 mg/L, but this 
concentration would not have been completely taken up by the organism.  These results 
showed that 96 hours of waterborne exposure to 1 mg/L E2 was not sufficient to induce 
VTG in female rainbow trout.  It is possible that if the potent hormone E2 is not able to 
induce estrogenic effects in 96 hours, any potential effects caused by ibuprofen would not 
be detected either. 
To determine potential estrogenic effects of ibuprofen on rainbow trout, the 
chronic exposure experiment was undertaken.  Overall total plasma protein 
concentrations indicated that treatments exposed to E2, including the E2 control and the 
mixed E2-ibuprofen treatment, had significantly greater plasma protein concentrations 
than the controls and the other ibuprofen treatments.  This trend was apparent over all 3 
sampling periods and directly correlated to the VTG results.  Overall VTG data showed 
that the E2 control, 1000 µg/L ibuprofen treatment as well as the mixed E2-ibuprofen 
treatment showed significantly greater VTG concentrations than the control group.  In 
relation to the sampling time, it is important to recognize that the E2 control and E2-
ibuprofen mixed treatments always displayed greater VTG concentrations, and it was not 
until day 56 that all three ibuprofen treatments were significantly greater than the control. 
With all of the ibuprofen treatments showing increased VTG concentrations, this 
suggests the possible estrogenic activity of ibuprofen.  The NSAID diclofenac increased 
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VTG expression levels in male Japanese medaka following 96 hours of exposure to 
concentrations as low as 1 µg/L with sampling occurring at 12 hours, 1, 2, and 4 days 
(Hong et al., 2007).  This study thus suggests that non-steroidal anti-inflammatory drugs 
are capable of endocrine disruption via estrogenic effects (Hong et al., 2007).  
 A recent study by Han et al. (2010) investigated the relationship between 
ibuprofen and steroidogenesis in Japanese medaka and a human adrenocortical carcinoma 
cell line (H295R).  This research made two main observations.  First, through the use of 
the cell line, they found that ibuprofen increased E2 production in a dose-dependent 
manner (Han et al., 2010).  Secondly, they found that ibuprofen increased VTG 
concentrations in male fish (Han et al., 2010).  They also showed that in addition to 
increased E2 concentrations in the ibuprofen exposed treatments, there was also increased 
aromatase activity (Han et al., 2010).   
Aromatase is a cytochrome P450 enzyme (CYP19) that is responsible for the 
biosynthesis of estradiols from androgens (Brueggemeier et al., 2005).  This finding 
contradicted other published research investigating the link between aromatase and COX 
(Brueggemeier et al., 2006).  Localized production of PGs can affect aromatase activity.  
PGE2 can influence estrogen synthesis by increasing the concentration of cyclic AMP 
(cAMP) (Brueggemeier et al., 2006).  It is believed that without the presence of PGs, 
caused by COX inhibition, the activity of aromatase would also be decreased 
(Brueggemeier et al., 2006). 
The research presented here has similar trends to that of Han et al. (2010).  The 
ibuprofen exposures may have caused increased E2 levels in the fish, which could 
stimulate the production of VTG, increasing the levels compared to the controls.  To 
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confirm this trend, the E2 levels as well as the aromatase activity in the ibuprofen treated 
samples should be measured.  The exact mechanism by which ibuprofen increases E2 and 
VTG concentrations is not known and more research needs to be done in this field. 
 
5.5 EROD Activity 
 Measured EROD activity from the acute exposure showed that there were no 
significant differences between the treatments and the controls.  Changes in EROD 
activity were only observed in the chronic exposure experiment. 
 At the end of the chronic exposure, it was determined that all of the treatment 
groups, other than the 32 µg/L ibuprofen exposure, had EROD activity that was 
significantly lower than the controls.  It would appear that ibuprofen was able to inhibit 
EROD activity in trout liver tissue. 
 In addition to the ibuprofen treatments, the E2 control also showed significant 
reduction in EROD activity.  It has been well studied that E2 has the ability to inhibit 
CYP1A activity ( Elskus, 2004; Navas & Segner, 2000; Whyte et al., 2000).  Navas & 
Segner (2000), using cultured rainbow trout hepatocytes, demonstrated that maturing 
female fish, or fish exposed to E2, suppress hepatic CYP1A protein levels and EROD 
activity.  Although the mechanism is unknown, it is believed that there is a relationship 
between the E2 receptors and estrogen responsive elements in the CYP1A gene (Navas & 
Segner, 2000).  They also found that levels of E2 capable of suppressing EROD activity 
were similar to those able to induce VTG production (Navas & Segner, 2000).  This 
concept was backed up by Elskus (2004).  Again using rainbow trout primary 
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hepatocytes, they showed that E2 could inhibit EROD activity in cells that were treated 
with a potent EROD inducer (Elskus, 2004).  
This trend was supported in the current study, although not until day 56 when a 
significant reduction in activity was measured in the E2 control as well as the mixed E2-
ibuprofen treatment.  This is different from published data where inhibition was apparent 
in acute studies, but the designs of the experiments were different.  In those works, 
inhibition was measured using tissue cultures allowed to soak in the hormone directly, 
whereas this experiment used in vivo exposures to waterborne E2 concentrations.  The 
concentration received by the fish would be less than the concentrations in the tank (1 
mg/L), so this may be responsible for the delay in observed inhibition. 
 On the other hand, there are conflicting reports about the effects of NSAIDs on 
EROD activity.  Work published on the NSAID diclofenac show the drug induces as well 
as inhibits EROD.  Laville et al. (2004) demonstrated that diclofenac was able to inhibit 
EROD activity in rainbow trout hepatocytes using tissue cultures.  In contrast, acute work 
done with Japanese medaka utilizing real-time PCR showed diclofenac was able to 
induce CYP1A gene expression in liver tissue (Hong et al., 2007).  A 9.3-fold induction 
was measured at 1 µg/L whereas a 64-fold induction was measured at a diclofenac 
concentration of 8 mg/L (Laville et al., 2004).  This indicated that at low concentrations 
the NSAID is a weak inducer while it is a moderate inducer at higher concentrations 
(Whyte et al., 2000). 
 When focusing on ibuprofen specifically, there are also conflicting reports.  A 48 
hour exposure of rainbow trout hepatocytes to ibuprofen showed no change in measured 
EROD activity (Gagne et al., 2006).  This was the same result as published by Thibaut et 
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al. (2006).  Ibuprofen showed no inhibition of EROD activity in carp (Cyprinus carpio) 
liver (Thibaut et al., 2006).   When Thibaut and Porte (2008) measured the effects of 
ibuprofen on a cell line from topminnow (Poeciliopsis lucida) for a time study they found 
that ibuprofen induced EROD activity.  EROD activity was measured at 3, 6 and 12 
hours at ibuprofen concentrations of 0.1, 1, 10 and 20 µM and ibuprofen induced EROD 
activity at a concentration of 10 µM at 6 hours only (Thibaut & Porte, 2008).  No other 
induction was observed at any other concentration at any other sampling period. 
 The results of the chronic experiment show that there was inhibition of EROD 
activity in some of the ibuprofen treatments.  The 1 µg/L ibuprofen exposure showed 
significant inhibition of EROD compared to the control on day 14, but the activity levels 
increased to similar to the control by day 28.  Also, the 1000 µg/L treatment showed 
inhibition of activity on day 28 but not on day 14 or 56.  The 32 µg/L treatment did not 
show inhibition at any of the sampling times measured.   
The mixed E2-ibuprofen treatment followed a pattern similar to the E2 control by 
only being significantly different from the control at day 56.  As stated previously, the 
1000 µg/L treatment did not show reduced EROD activity on the last sampling period 
and the E2-ibuprofen mixed treatment did, but the small sample size for the mixed 
treatment on day 56 (n = 3) may have skewed the results.  To get a better idea of the 
mixture effects of E2 and ibuprofen on EROD activity, the experiment would need to be 
repeated to ensure enough samples were measured from the mixed E2-ibuprofen 
treatment.   
The lack of apparent trends in the data may be due to the fact that ibuprofen may 
act as both an inhibitor as well as an inducer of EROD activity, depending on the 
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concentration and length of exposure (Thibaut & Porte, 2008).  To definitively determine 
the effects of ibuprofen on rainbow trout in vivo, more experiments need to be completed.  
Acute studies measuring EROD activity more frequently using a wide range of 








































 The purpose of this research was to evaluate the effects of ibuprofen on rainbow 
trout following acute and chronic exposures.  The main objectives were to evaluate if 
COX activity was inhibited in various tissues, if ibuprofen was able to elicit estrogenic 
effects by measuring plasma VTG concentrations and if EROD activity was altered 
following exposure.  Upon analysis, it was found that there were no changes in gill and 
kidney tissue COX activities following a 96 hour and 8 week exposure to ibuprofen.  
VTG concentrations were measured and although no change was determined in the acute 
exposure, slight estrogenic effects were detected in the chronic experiment.  By day 56 of 
the chronic exposure, all of the ibuprofen treatments showed significantly greater VTG 
concentrations when compared to the controls.  Lastly, no change in EROD activity was 
observed in the acute experiment, but every treatment in the chronic exposure except the 
32 µg/L ibuprofen treatment displayed significantly reduced EROD activity.  There are 
many conflicting reports in the literature regarding ibuprofen’s effect on EROD, 
indicating that this endpoint needs more research to evaluate its utility as a biomarker of 
exposure to ibuprofen.   
 Many aspects of the effects of ibuprofen on aquatic organisms, including rainbow 
trout, still need to be evaluated.  It has been well studied that ibuprofen is an inhibitor of 
the COX enzyme, but research has shown that there is an apparent lack of inhibition in 
fish (Cavallaro & Burnside, 1988; Flippin et al., 2007; Lister & van der Kraak, 2008).  In 
regards to VTG, the mechanisms by which ibuprofen can increase these levels are not 
understood. It is believed that ibuprofen can increase E2 levels, leading to an increase in 
vitellogenin, but the pathway for this hormonal increase has not been elucidated (Han et 
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al., 2010).  The effect on EROD activity is also poorly understood.  In addition to 
ibuprofen, other pharmaceuticals from the class of non-steroidal anti-inflammatory drugs, 
such as diclofenac, have had conflicting data published.  Both ibuprofen and diclofenac 
have been stated to inhibit as well as induce EROD activity (Gagne et al., 2006; Hong et 
al., 2007; Laville et al., 2004; Thibaut & Porte, 2008).  The results of EROD activity 
from the chronic exposure show that ibuprofen may act as an inhibitor of activity, but 
more work needs to be completed before definitive conclusions can be made.  It is these 
inconsistencies regarding the effects of ibuprofen in the aquatic environment that 
necessitate more work be focused in this field. 
 With North America dominating the market on pharmaceutical sales, the concern 
about PPCPs in the environment is not going to diminish (Corcoran et al., 2010).  
NSAIDs are one of the most prescribed drug classes and are commonly found in WWTP 
effluents and surface waters (Christen et al., 2010).  Because of their presence in the 
environment, more work needs to go into studying ibuprofen and its interactions with 
fish.  The effects of ibuprofen appear to be different in various aquatic organisms so well 
designed experiments are necessary to build the knowledge base (Han et al., 2010).  The 
results of the outlined experiment are just one step towards understanding the effects of 
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Settings used for the UPLC-MS system.   These parameters were used for (A) the 















Calibration standards prepared for the Bradford protein assay.  The bovine serum 
albumin (BSA) solution used was prepared by diluting 1 mg of BSA in 1 mL of Milli-Q 
water, creating a 1 mg/mL BSA solution.  All standards were prepared in 1.5 mL 





Volume (µL) Concentration BSA 
(mg/mL) BSA Solution Milli-Q Water 
1 0 500 0 
2 25 225 0.1 
3 50 200 0.2 
4 100 150 0.4 
5 150 100 0.6 


















Calibration standards prepared for the VTG ELISA.  The VTG standard was prepared by 
diluting 10 µg of VTG obtained from the distributer in 1000 µL 1x phosphate buffered 
saline (PBS).  This solution was then divided into aliquots of 80 µL, which were thawed 





Volume (µL) Concentration 
VTG (ng/mL) VTG Standard Coating Buffer 
1 0.7 332.6 25 
2 1.4 331.9 50 
3 2.8 330.6 100 
4 6.9 326.4 250 
5 13.9 319.4 500 
6 20.8 312.5 750 
















Calibration standards prepared for the EROD activity assay.  Ten microlitres of the 
resorufin working solution were diluted in 4990 µL of HEPES grinding buffer to prepare 
the working stock/HEPES solution.  All solutions were prepared in 1.5 mL 












1 0 1000 0.0 
2 200 800 1.0 
3 400 600 2.0 
4 600 400 3.0 

























Condition factor (K) calculated from the acute ibuprofen exposure experiment.  Bars 
represent mean ± SD.  All treatments n=8, except E2 control, Ibu 1 mg/L and mixed E2-


































Gonad somatic index (GSI) calculated from the acute ibuprofen exposure experiment.  
Bars represent mean ± SD.  All treatments n=8, except E2 control, Ibu 1 mg/L and mixed 








































Condition factor (K) calculated from the chronic ibuprofen exposure experiment. (A) 
Data from all 3 sampling periods (day 14, 28, 56) have been pooled. Bars represent mean 
± SD.  n = 30 for all treatments except Ibu 32 µg/L (n=25), Ibu 1000 µg/L (n=28) and 
mixed 1000 µg/L E2 + 1000 µg/L treatment (n=20). (B) Bars represent mean ± SE. n = 
10 for all treatments except 32 µg/L (n=10, n=9, n=6), 1000 µg/L (n=9, n=11, n=8) and 











































































Ibu 1 ug/L 
Ibu 32 ug/L 













Gonad somatic index (GSI) calculated from the chronic ibuprofen exposure experiment. 
(A) Data from all 3 sampling periods (day 14, 28, 56) have been pooled. Bars represent 
mean ± SD.  n = 30 for all treatments except Ibu 32 µg/L (n=25), Ibu 1000 µg/L (n=28) 
and mixed 1000 µg/L E2 + 1000 µg/L treatment (n=20). (B) Bars represent mean ± SE. n 
= 10 for all treatments except 32 µg/L (n=10, n=9, n=6), 1000 µg/L (n=9, n=11, n=8) and 






















































































Ibu 1 ug/L 
Ibu 32 ug/L 
Ibu 1000 ug/L 
Mixed 
 
